Genetic Analysis of Insulin and Insulin-like Growth Factor-1 Signaling in the Central Nervous System by Koch, Linda
  
 
Genetic Analysis of Insulin and  
Insulin-like Growth Factor-1 Signaling  
in the Central Nervous System 
 
 
 
Inaugural-Dissertation 
zur 
Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultät  
der Universität zu Köln 
vorgelegt von 
 
 
Linda Koch 
aus Köln 
 
 
 
Köln 2007 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Berichterstatter:  Prof. Dr. Jens Brüning 
 Prof. Dr. Thomas Langer 
 
 
 
 
Tag der mündlichen Prüfung: 06.02.2008 
 
 
  Table of contents 
-III-   
Figure Index _________________________________________________________ VI 
Table Index __________________________________________________________ IX 
Abbreviations__________________________________________________________X 
1 Introduction ______________________________________________________ 1 
1.1 Diabetes mellitus ________________________________________________________1 
1.2 Insulin ________________________________________________________________2 
1.2.1 Structure and Biosynthesis ________________________________________________________2 
1.2.2 Metabolic Effects _______________________________________________________________2 
1.3 The Insulin Receptor ____________________________________________________3 
1.3.1 Molecular Mechanisms of Insulin Signaling __________________________________________4 
1.4 Conditional Gene Targeting ______________________________________________6 
1.4.1 Generation of loxP-flanked Alleles _________________________________________________6 
1.4.2 Cre-transgenic Mice _____________________________________________________________7 
1.5 RNA interference _______________________________________________________9 
1.5.1 Small hairpin RNAs ____________________________________________________________10 
1.6 Mouse Mutants of Insulin and IGF-1 Receptor Signaling _____________________11 
1.7 Insulin and IGF-1 Receptor Signaling Redundancy __________________________12 
1.7.1 Insulin and IGF-1 Signaling in the CNS_____________________________________________14 
1.7.2 IGF-1 Signaling in Learning and Memory Formation __________________________________15 
1.8 Objectives ____________________________________________________________16 
2 Material and Methods _____________________________________________ 17 
2.1 Chemicals_____________________________________________________________17 
2.2 Molecular Biology______________________________________________________19 
2.2.1 Isolation of Genomic DNA_______________________________________________________19 
2.2.2 Quantification of Nucleic Acids ___________________________________________________19 
2.2.3 Polymerase Chain Reaction (PCR)_________________________________________________20 
2.2.4 Southern Blot Analysis__________________________________________________________20 
2.2.5 RNA Extraction, RT PCR and Quantitative Realtime PCR ______________________________21 
2.2.6 ELISA_______________________________________________________________________22 
2.3 Cell Biology ___________________________________________________________23 
2.3.1 Gene Targeting and Generation of IGF-1RΔSyn Mice ___________________________________23 
2.3.2 Histological Analysis and Immunohistochemistry _____________________________________24 
2.4 Biochemistry __________________________________________________________25 
2.4.1 Protein Extraction______________________________________________________________25 
2.4.2 Western Blot Analysis __________________________________________________________25 
2.5 Mouse Experiments ____________________________________________________26 
2.5.1 Animals _____________________________________________________________________26 
2.5.2 Experimental Setup ____________________________________________________________27 
2.5.3 Body Weight and Blood Glucose Levels ____________________________________________28 
2.5.4 Food Intake___________________________________________________________________28 
2.5.5 Glucose and Insulin Tolerance Test ________________________________________________28 
2.5.6 Glucose-stimulated Insulin Secretion_______________________________________________28 
2.5.7 Insulin Signaling_______________________________________________________________28 
2.5.8 Intracerebroventricular Insulin Infusion _____________________________________________29 
2.5.9 Leptin Restoration _____________________________________________________________29 
2.5.10 Kainic Acid-induced Seizures ____________________________________________________29 
2.5.11 Analysis of Body Composition____________________________________________________30 
2.5.12 Behavioral Analysis ____________________________________________________________30 
2.6 Computer Analysis _____________________________________________________32 
Table of contents   
 
-IV- 
2.6.1 Densitometrical Analysis________________________________________________________ 32 
2.6.2 Statistical Methods_____________________________________________________________ 32 
3 Results _________________________________________________________ 33 
3.1 Inducible inactivation of the insulin receptor gene in peripheral tissues of adult mice  
 _____________________________________________________________________ 33 
3.2 Inducible inactivation of the insulin receptor in peripheral tissues and the central 
nervous system of adult mice ____________________________________________ 39 
3.3 Combined central and peripheral insulin resistance leads to a more severe 
lipodystrophy than peripheral insulin resistance____________________________ 41 
3.4 Intracerebroventricular infusion of insulin leads to increased lipogenesis _______ 43 
3.5 Insulin inhibits adipocyte-autonomous leptin secretion ______________________ 46 
3.6 Peripheral and central insulin action regulate hepatic ObRb expression ________ 48 
3.7 Central insulin action regulates hepatic IL-6 mRNA levels ___________________ 51 
3.8 IRΔwb mice display a higher degree of impaired peripheral glucose metabolism __ 52 
3.9 Leptin administration improves glucose metabolism in IRΔwb mice_____________ 54 
3.10 Peripheral insulin resistance results in β cell hyperplasia but unaltered insulin 
secretion _____________________________________________________________ 56 
3.11 Targeted disruption of the IGF-1 receptor allele ____________________________ 59 
3.12 Conditional inactivation of the IGF-1 receptor gene in the central nervous system 62 
3.13 Physiological characterization of IGF-1RΔSyn mice __________________________ 66 
3.13.1 Energy homeostasis ____________________________________________________________ 66 
3.13.2 Glucose homeostasis ___________________________________________________________ 68 
3.14 Brain weight is unaffected by central IGF-1R deficiency _____________________ 70 
3.15 Unaltered susceptibility to kainic acid of IGF-1RΔSyn mice ____________________ 71 
3.16 Central IGF-1 receptor deficiency results in loss of spatial memory formation and 
anxiety-like behavior___________________________________________________ 73 
4 Discussion ______________________________________________________ 77 
4.1 Inducible mouse models of insulin resistance_______________________________ 77 
4.2 Peripheral versus central insulin signaling_________________________________ 78 
4.2.1 The role of central insulin action in lipogenesis ______________________________________ 78 
4.2.2 Insulin-mediated inhibition of adipocyte-autonomous leptin secretion_____________________ 80 
4.2.3 Hepatic Stat-3 activation and its role in peripheral glucose homeostasis ___________________ 82 
4.2.4 Effects of peripheral and central insulin deficiency on insulin concentrations and its secretion from 
the pancreatic β cell ____________________________________________________________ 83 
4.3 IGF-1 receptor signaling in the central nervous system ______________________ 84 
4.3.1 Contribution of central IGF-1 receptor signaling to insulin-mediated effects in the periphery ___ 84 
4.3.2 Neuroprotective effects of IGF-1 receptor signaling ___________________________________ 85 
4.3.3 IGF-1 receptor signaling in learning and memory formation ____________________________ 86 
4.4 Perspectives and experimental approaches ________________________________ 86 
5 Summary _______________________________________________________ 88 
6 Zusammenfassung _______________________________________________ 89 
7 References ______________________________________________________ 91 
8 Acknowledgements ______________________________________________ 113 
  Table of contents 
-V-   
9 Erklärung______________________________________________________ 114 
10 Curriculum Vitae________________________________________________ 115 
Figure Index   
 
-VI- 
Figure Index 
Fig. 1: Metabolic effects of insulin signaling................................................................................ 3 
Fig. 2: Insulin signal transduction pathway................................................................................... 5 
Fig. 3: General scheme of the ligand-activated CreLBD fusion protein. ...................................... 8 
Fig. 4: RNA interference. ............................................................................................................ 10 
Fig. 5: General scheme of the inducible peripheral insulin receptor knockout mouse (IRΔper). .. 33 
Fig. 6: Genomic map of the mouse insulin receptor locus surrounding exon 4. ......................... 34 
Fig. 7: Southern blot analysis of insulin receptor recombination................................................ 34 
Fig. 8: Western blot analysis of insulin receptor expression....................................................... 36 
Fig. 9: Insulin receptor deficiency in peripheral organs of IRΔper mice. ...................................... 37 
Fig. 10: Abrogated insulin signaling in peripheral organs of IRΔper mice. .................................. 38 
Fig. 11: General scheme of the inducible whole body insulin receptor knockout mouse (IRΔwb).
..................................................................................................................................................... 39 
Fig. 12: Insulin receptor deficiency in central and peripheral organs of IRΔwb mice................... 40 
Fig. 13 Changes in body weight in insulin receptor deficient mice. ........................................... 41 
Fig. 14: Reduction of white adipose tissue mass in insulin receptor deficient mice. .................. 42 
Fig. 15: Body composition in insulin receptor deficient mice. ................................................... 42 
Fig. 16: Adipose tissue-specific hypoplasia in IRΔwb mice.......................................................... 43 
Fig. 17: Chronic icv infusion of insulin has no effect on peripheral insulin concentrations in 
C57BL/6 mice. ............................................................................................................................ 44 
Fig. 18: Chronic icv infusion of insulin increases adipose tissue mass without changes in body 
weight or food intake in C57BL/6 mice. ..................................................................................... 45 
Fig. 19: Chronic icv infusion of insulin increases lipogenesis in C57BL/6 mice. ...................... 46 
Fig. 20: Peripheral insulin resistance results in an increase in total serum leptin concentrations.
..................................................................................................................................................... 46 
Fig. 21: Whole body insulin resistance results in a decrease in total serum leptin concentrations.
..................................................................................................................................................... 47 
Fig. 22: Serum adipokine levels correlated with white adipose tissue mass in insulin receptor 
deficient mice. ............................................................................................................................. 47 
Fig. 23: Peripheral and central insulin receptor deficiency increases hepatic ObRb mRNA 
expression.................................................................................................................................... 48 
Fig. 24: Peripheral and central insulin receptor deficiency increases hepatic ObRb protein 
expression.................................................................................................................................... 49 
Fig. 25: Peripheral but not central insulin receptor deficiency results in an increase in hepatic 
Stat-3 phosphorylation. ............................................................................................................... 50 
  Figure Index 
-VII-   
Fig. 26: Peripheral insulin receptor deficiency results in an increase in hepatic IL-6 mRNA 
expression.................................................................................................................................... 51 
Fig. 27: Unaltered IL-6 mRNA expression in the liver of IRΔwb mice. ....................................... 52 
Fig. 28: Loss of central insulin receptor signaling results in more pronounced hyperglycemia. 53 
Fig. 29: Impaired glucose tolerance in IRΔper mice...................................................................... 53 
Fig. 30: Impaired glucose tolerance in IRΔwb mice. ..................................................................... 54 
Fig. 31: Restoration of serum leptin concentrations of IRΔwb mice............................................. 55 
Fig. 32: Chronic infusion of leptin increases hepatic Stat-3 phosporylation in IRΔwb mice. ....... 55 
Fig. 33: Restoration of hepatic Stat-3 phosporylation ameliorates blood glucose concentrations.
..................................................................................................................................................... 56 
Fig. 34: Peripheral and whole body insulin receptor deficiency results in hyperinsulinemia..... 57 
Fig. 35: Glucose-stimulated insulin secretion in IRΔper and IRΔwb mice. ..................................... 57 
Fig. 36: Peripheral and central insulin resistance results in β cell hyperplasia........................... 58 
Fig. 37: Increased β cell mass in IRΔper and IRΔwb mice. ............................................................. 59 
Fig. 38: Conditional gene targeting strategy. .............................................................................. 60 
Fig. 39: Correct construct integration into the endogenous IGF-1 receptor locus. ..................... 60 
Fig. 40: Chimeras heterozygous for the mutated IGF-1 receptor allele. ..................................... 61 
Fig. 41: Germline transmission of the mutated IGF-1 receptor allele......................................... 61 
Fig. 42: Central IGF-1 receptor protein expression. ................................................................... 63 
Fig. 43: Peripheral IGF-1 receptor protein expression................................................................ 64 
Fig. 44: Synapsin Cre expression in brain regions of SynCre-LacZ mice. ................................. 65 
Fig. 45: Reduced IGF-1 receptor expression in the dentate gyrus of IGF1RΔSyn mice................ 66 
Fig. 46: Body weight of IGF-1RΔSyn mice................................................................................... 67 
Fig. 47: Unaltered body composition of IGF-1RΔSyn mice.......................................................... 67 
Fig. 48: Central IGF-1 receptor deficiency has no impact on adipose tissue mass or serum leptin 
and insulin concentrations........................................................................................................... 68 
Fig. 49: Loss of central IGF-1 receptor signaling has no impact on blood glucose 
concentrations. ............................................................................................................................ 69 
Fig. 50: Unaltered glucose tolerance in IGF-1RΔSyn mice. .......................................................... 69 
Fig. 51: Unaltered insulin sensitivity in IGF-1RΔSyn mice. .......................................................... 70 
Fig. 52: Unaltered brain weight of IGF-1RΔSyn mice. ................................................................. 71 
Fig. 53: Central IGF-1 receptor deficiency has no impact on kainic acid-induced seizures....... 72 
Fig. 54: Kainic acid-induced neuronal damage occurs to similar extent in IGF-1RΔSyn and 
control mice................................................................................................................................. 73 
Fig. 55: Spatial navigation working memory is impaired in IGF-1RΔSyn mice. .......................... 74 
Fig. 56: IGF-1RΔSyn mice do not display signs of anxiety........................................................... 74 
Figure Index   
 
-VIII- 
Fig. 57: Unaltered motor coordination in IGF-1RΔSyn mice. ....................................................... 75 
Fig. 58: Unaltered spontaneous novelty preference and exploratory activity in IGF-1RΔSyn mice.
..................................................................................................................................................... 76 
Fig. 59: Proposed model for insulin action in the CNS and in the periphery in the regulation of 
glucose and adipose tissue metabolism. ...................................................................................... 80 
Fig. 60: Proposed model for the effects of insulin resistance on circulating leptin levels. ......... 81 
  Table Index 
-IX-   
Table Index 
Table 1: Excerpt of transgenic and knockout mouse models involving genes of the insulin or 
IGF-1 receptor signaling pathway.....................................................................................................12 
Table 2: Chemicals............................................................................................................................19 
Table 3: Oligonucleotides used for genotyping. ...............................................................................20 
Table 4: Oligonucleotides used to amplify the Southern blot probes. ..............................................21 
Table 5: Probes used for Realtime PCR............................................................................................22 
Table 6: Primary antibodies used for Western blot analysis. ............................................................26 
Abbreviations   
-X- 
Abbreviations 
 
aa    amino acid 
Akt    proteinkinase B 
Avertin   tribromoethyl alcohol and tert-amyl alcohol 
β-me    β-mercaptoethanol 
bp    base pair 
c    DNA concentration 
C    cytosine 
°C    degrees Celsius 
cDNA    complementary DNA 
cpm    counts per minute 
Cre    site-specific recombinase (causes recombination) 
CreERT2   Cre recombinase and mutated ER-LBD fusion protein 
Ctrl    Control 
ddH2O    double destilled water 
DEPC    diethylpyrocarbonate 
dNTP    desoxynucleotide-triphosphate 
DMSO   dimethylsulfoxide 
DNA    desoxyribonucleic acid 
ds    doublestranded 
DTT    1,4-Dithio-DL-threitol 
E2    17-β-estradiol 
ECL    enhanced chemiluminescence 
EDTA    ethylene-diaminetetraacetic acid 
EF    embryonic fibroblasts 
ER    estrogen receptor 
ERT2    mutated ligand binding domain of the human ER 
ES    embryonic stem 
EtBr    ethidium bromide 
G    guanine 
G418    geneticin 
  Abbreviations 
-XI-   
GTT    glucose tolerance test 
h    hour 
HEPES   N-2-hydroxyethylpiperazine-N’-2-ethansulfonic acid 
HR    homologous recombinant 
HRE    hormone response element 
HSV-tk   thymidine kinase of the Herpes simplex virus 
icv    intracerebroventricular 
IGF-1R   insulin-like growth factor-1 receptor 
i.p.    intraperitoneal 
IR    insulin receptor 
IRS    insulin receptor substrate 
ITT    insulin tolerance test 
KA    kainic acid 
kbp    kilobase pairs 
kDa    kilodalton 
loxP    locus of x (crossing) over of P1 
min    minute 
NaCl    sodium chloride 
NaOH    sodium hydroxide 
neor    neomycine resistance gene 
LBD     ligand binding domain 
NLS     nuclear localization sequence 
OD    optical density 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
per    peripheral 
PH    pleckstrin homology 
PI3K    phosphatidylinositol-3 kinase 
PIP2     phosphatidylinositol-4,5-biphosphate 
PIP3     phosphatidylinositol-3,4,5-triphosphate 
p.o.    per os 
PTB    phosphotyrosine binding 
RNA    ribonucleic acid 
RNAi    RNA interference 
Abbreviations   
-XII- 
rpm    rounds per minute 
RT    room temperature 
sec    second 
s.c.    subcutaneous 
SDS    sodium dodecyl sulfate 
SH    src homology 
shRNA   small/short hairpin RNA 
siRNA    small interfering RNA 
ss    singlestranded 
SSC    sodium chloride/ sodium citrate buffer 
TAE    Tris-acetic acid-EDTA buffer 
Taq Pol   polymerase from Thermus aquaticus 
TE    Tris-EDTA buffer 
Tris    2-amino-2-(hydroxymethyl-)1,3-propandiole 
TWEEN   polyoxethylene-sorbitan-monolaureate 
U    units 
v/v    volume per volume 
WAT    white adipose tissue 
wb    whole body 
w/v    weight per volume 
wt    wildtype 
5’    five prime end of DNA sequences 
3’    three prime end of DNA sequences 
  Introduction 
-1-   
1 Introduction 
1.1 Diabetes mellitus 
Diabetes mellitus is a chronic disease, accounting for an estimated 224.000 deaths 
every year in the United States (US) alone, establishing itself as the 6th leading cause of 
death. As of 2005, an estimate of 7% of the US population, approximately 20.8 million 
people, suffers from diabetes. Diabetes and complications arising from it cost an 
estimated $132 billion each year in terms of healthcare and lost productivity in the US 
(1). 
The first reference to diabetes is attributed to an Egyptian papyrus, written as 
early as 1550 BC, which describes remedies for the treatment of excessive urination. 
Around 100 AD, Areteus, a disciple of Hippocrates, provided the first accurate 
description of the disease and termed it “diabetes”, based on the Greek word diabainein, 
“to pass through”, a reference to the polyuria, one of its major symptoms (for review 
see (2, 3)). Not until the late 18th century, the physicians Johann Peter Frank and John 
Rollo appended the Latin term “mellitus”, for honey, to distinguish diabetes from other 
diseases causing polyuria (for review see (4)). 
In the early modern period, one of the first publicized works relating to diabetes 
originates from 1675, when the British physician Thomas Willis found the urine of 
diabetic patients to be abnormally sweet (5), an observation which was confirmed a 
century later, in 1776, by his compatriot and colleague Matthew Dobson. Dobson also 
found that sugar was not only present in the urine but in the blood of patients, thereby 
establishing the systemic nature of the disorder (6). Twelve years later, the physician 
Thomas Cawley first noted a correlation between diabetes and damaged pancreas while 
performing an autopsy on a diabetic patient, yet his observation would not be 
acknowledged for another hundred years (7). In 1889, the Polish-German physician 
Oscar Minkowski and his German colleague Joseph von Mering discovered that after 
surgical removal of the pancreas, dogs displayed all symptoms associated with diabetes 
and died shortly afterwards, providing the first link between the pancreas and diabetes 
((8), (for review see (9)). However, although it had been deduced by several scientists 
that a substance must be secreted from the pancreas to regulate carbohydrate 
metabolism and that loss of this substance causes diabetes (10), it was not until 1921 
that physician Frederick Banting and medical student Charles Best in the lab of J.J.R. 
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MacLeod at the University of Toronto finally made the discovery which would 
revolutionize the treatment of diabetes mellitus (11). In 1923, Banting and MacLeod 
were awarded the Nobel Prize in Medicine for their discovery of insulin. 
 
1.2 Insulin 
1.2.1 Structure and Biosynthesis 
Insulin is synthesized in the β cells of the pancreatic islets of Langerhans, 
endocrine cells within the predominantly exocrine pancreatic tissue. It is cleaved from 
an inactive precursor, proinsulin, consisting of two peptide chains linked by a third, the 
so-called C-peptide (12). Proinsulin is synthesized in the endoplasmatic reticulum, then 
transported to the Golgi apparatus where it is packed into secretory granules (13). 
Within these vesicles, it is processed to insulin through site-specific proteolytic 
cleavage by two endopeptidases and one carboxypeptidase (14-16). The C-peptide is 
removed from proinsulin, leading to a conformational change of the protein which 
enables the interaction of the mature molecule with its receptor, the insulin receptor 
(17). After binding to and activating its receptor, insulin is either returned into the 
circulation intact or internalized and degraded by the Insulin-degrading enzyme (for 
review see (18)). 
 
1.2.2 Metabolic Effects 
 
Elevated plasma glucose concentration (hyperglycemia) is the predominant 
stimulus causing insulin secretion from the pancreatic β cells into the bloodstream, 
although insulin is also secreted in response to glucagon, adrenalin or increased amino 
acid concentrations. Activation of insulin signaling results in the translocation of the 
glucose transporter GLUT-4 into the cell membrane of skeletal muscle cells and 
adipocytes, thereby increasing glucose uptake into these tissues (19-21). In addition to 
glucose clearance from the blood, insulin increases glycolysis and inhibits its reverse 
process, gluconeogenesis (for review see (22)). Concomitantly, insulin promotes the 
storage of substrates by stimulating amino acid uptake and protein synthesis in muscle, 
glycogen synthesis in liver and lipogenesis in adipose tissue. Catabolic processes, on the 
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other hand, such as glycogenolysis, lipolysis and proteolysis are inhibited by insulin 
(Fig. 1). 
 
 
 
Fig. 1: Metabolic effects of insulin signaling.  
Overview of insulin’s effects on the cellular level. Insulin signaling results in the increase of glucose and 
amino acid uptake, glycogen and protein synthesis, lipogenesis and glycolysis, while it inhibits 
gluconeogenesis, lipolysis and proteolysis (adapted from (23)). 
 
1.3 The Insulin Receptor 
 The family of ligand-activated receptor tyrosine kinases represents the connecting 
link between extra- and intracellular signal transduction of insulin and insulin-like 
peptides. This subfamily of receptor kinases comprises the insulin receptor, the insulin-
like growth factor (IGF)-1 receptor and an orphan receptor, known as the insulin 
receptor-related receptor (24-26). These receptors are heterotetrameric proteins, 
consisting of two αβ-dimers connected by disulfide bridges (27, 28). The α-subunits 
form an extracellular ligand binding domain, while the transmembrane region and the 
intracellular C-terminal part encompassing the intrinsic receptor tyrosine kinase activity 
are formed by the β-subunit (29-32). Each receptor is the product of a separate gene, 
whose transcript is translated into a precursor or proreceptor that, after removal of the 
precursor signaling peptide, is post-translationally processed by a furin-like enzyme to 
yield a single αβ-dimer (33).  
In humans, the gene encoding the insulin receptor is located on the short arm of 
chromosome 19, spanning a region of more than 120 kilobase pairs (kbp) which 
Introduction   
 
-4- 
comprise a total of 22 exons (34, 35). In mammals, insulin receptors are expressed in all 
tissues, including classic insulin responsive tissues such as skeletal muscle, liver and 
adipose tissue, as well as tissues previously thought to be unresponsive to insulin like 
the central nervous system, the pancreas or lymphatic cells (36-38). 
 
1.3.1 Molecular Mechanisms of Insulin Signaling 
 Insulin and the related insulin-like growth factor (IGF)-1 exert their pleiotropic 
functions by binding to and activating their membrane-bound tyrosine kinase receptors 
(25, 39, 40) (Fig. 2). Functionally, the insulin receptor acts as a classical allosteric 
enzyme. Ligand binding results in receptor autophosphorylation on three intracellular 
tyrosine residues of the β-subunits, thereby activating the intrinsic tyrosine kinase 
activity in the C-terminal region of the receptor (41). Upon autophosphorylation, 
intracellular signaling proteins are recruited to the receptor through their 
phosphotyrosine binding (PTB) domain and there become tyrosine phosphorylated (42-
44). In addition to the PTB domain, intracellular substrates contain an N-terminal 
Pleckstrin homology (PH) domain which, through interaction with inositol phosphates 
in the cell membrane, allows for the localization of the substrate to the membrane (45-
47). Intracellular signaling molecules of the insulin receptor are the insulin receptor 
substrates (IRS)-1-4 and the Grb2-associated binder (Gab)-1-4 proteins (48-54). These 
substrates, when tyrosine phosphorylated, serve as docking platforms for Src-homology 
(SH)-2 domain containing proteins such as the regulatory subunit of the 
phosphatidylinositol 3 kinase (PI3K), the growth factor receptor binding protein (Grb)-2 
and the SH-2 domain containing phosphatase (Shp)-2, among others, resulting in the 
activation of the PI3K and the Ras/Raf Mitogen-activated protein (MAP)-kinase 
pathway (55-59). The PI3K is a heterodimer consisting of a catalytic subunit, p110, 
constitutively associated with a regulatory subunit (for review see (60)). When 
activated, PI3K catalyzes the conversion of phosphatidylinositol-4,5-biphosphate (PIP2) 
to phosphatidylinositol-3,4,5-triphosphate (PIP3) (61, 62). PIP2 and PIP3 bind the PH 
domain of the serine/threonine kinase proteinkinase B, also termed Akt. This results in 
the recruitment of Akt from the cytosol to the membrane and a conformational change, 
which converts Akt into a substrate for the phosphoinositide-dependent kinase (Pdk)-1 
(for review see (63)). Activation of Akt controls a broad variety of biological functions 
such as the regulation of glycogen and protein synthesis, protection from apoptosis, 
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stimulation of glucose transport and the regulation of gene transcription (for review see 
(64)). 
 
Fig. 2: Insulin signal transduction pathway.  
Binding of insulin to the insulin receptor results in receptor trans-phosphorylation and activation leading 
to the recruitment and subsequent phosphorylation of insulin receptor substrates. This enables the binding 
of SH-2 domain containing proteins, which ultimately leads to the activation of downstream signaling 
pathways such as the PI3K or the MAPK signaling pathway. IR = insulin receptor, IRS = insulin receptor 
substrate, PI = Phosphatidylinositol, Pdk = phosphoinositide-dependent kinase, Akt = Proteinkinase B,  
FoxO1 = Forkhead transcription factor O1, Gsk3β = glycogen synthase kinase 3β, eIF2 = eukaryotic 
translation inititation factor 2, PDE3B = phosphodiesterase 3B, PKA = Proteinkinase A, HSL = hormone 
sensitive lipase = mTOR = mammalian target of rapamycin, p70S6K = p70 S6 kinase, Grb2 = growth 
factor receptor binding protein, SOS = son of sevenless, Ras = rat sarcoma, Raf = v-raf-leukemia viral 
oncogene, MEK = Mitogen-activated protein kinase kinase, ERK = extracellular signal-regulated kinase 
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1.4 Conditional Gene Targeting 
Manipulating the mouse genome using homologous recombination in embryonic 
stem cells has now been recognized as a technique so valuable for the analysis of gene 
function that its discoverers Mario R. Capecchi, Sir Martin J. Evans and Oliver Smithies 
were awarded the Nobel Prize in Physiology or Medicine 2007 ((65-67), for review see 
(68)). However, since this process involves the manipulation of the murine germline, 
conventional gene targeting results in the loss of gene function in all cells during pre- 
and postnatal development. Consequences to be considered are the occurrence of 
embryonic lethality, compensatory effects by redundant genes and side effects caused 
by the inserted selection marker. To circumvent these potential drawbacks, gene 
inactivation in a spatially and temporally controlled manner can be achieved by 
conditional gene targeting, a more sophisticated method based on sequence-specific 
DNA recombinases as tools for genetic engineering (for review see (69, 70). One of 
these site-specific DNA recombinases, the Cre (causes recombination) recombinase, is a 
38 kDa protein of the bacteriophage P1 that recognizes specific 34 bp palindromic 
sequences, termed loxP (locus of crossing (x) over in P1) sites (71, 72). Depending on 
the orientation of the loxP sites the Cre recombinase mediates the inversion, excision or 
translocation of the DNA sequence that is flanked by the two loxP sequences (73-76). 
DNA sequences flanked by directly repeating loxP sites are excised as a circular 
molecule, leaving a single loxP sequence at the site of recombination (73, 77).  
 
1.4.1 Generation of loxP-flanked Alleles 
Whereas conventional gene targeting results in the inactivation of a gene already 
in embryonic stem (ES) cells, the strategy of conditional mutagenesis is based on the 
flanking of an essential region in a gene of interest by loxP sequences in ES cells 
without interfering with the original gene function (70, 78). This approach requires the 
construction of a gene targeting vector, in which two loxP sites are flanking an 
indispensable gene segment, in most cases one or more exons. The loxP sites are placed 
within non-coding sequences to preserve gene integrity. Insertion of a selection marker 
is necessary for subsequent selection of homologous recombinants. The selection 
marker in turn is flanked by so-called FRT sequences, to later enable its excision from 
the genome of the ES cells by a transient transfection of the cells with a Flp 
recombinase-coding plasmid (79). Alternatively, mice still containing the selection 
  Introduction 
-7-   
marker within their DNA can be crossed to mice expressing the Flp recombinase in 
their germline. The Flp/FRT system is the eukaryotic homolog of the Cre/loxP system, 
originating from the yeast Saccharomyces cerevisiae. FRT sites consist of two 13 bp 
long sequences immediately flanking an 8 bp long asymmetrical core sequence (80). 
Hence, the final gene targeting construct consists of, from 5’ to 3’, a sequence 
homologous to the target gene sequence, a loxP site, an FRT-flanked selection marker 
cassette, a second homologous sequence that contains essential regions of the targeted 
gene, a second loxP site, and a third homologous gene sequence.  
The construct is introduced into murine ES cells via electroporation. Cells that 
have integrated the construct through homologous recombination can be selected for 
with the help of the selection marker and determined by Southern blot and PCR 
analyses (81, 82). The construct is integrated only into one of the two alleles of a gene, 
rendering ES cells heterozygous for the desired mutation. A homologous recombinant 
ES cell clone is injected into a murine embryo at the blastocyst stage, where it integrates 
into the inner cell mass of the embryo and participates in the continuing embryonic 
development (83-85). The blastocysts are implanted into the uterus of pseudopregnant 
mice. Since the injected ES cell clones can partake in the development of all organs, 
they can also differentiate into germ cells. All tissues of the resulting offspring, so-
called chimeras, consist of two cell types of different origin. When mutated ES cells 
make up the chimeras germline, the mutation is passed on to its offspring. Further 
intercrosses yield mice homozygous for the recombinant locus (83, 84, 86, 87). 
 
1.4.2 Cre-transgenic Mice 
Cre-transgenic mouse strains are generated either by conventional random 
transgenics, targeted insertion into a gene (knock-in) or by generating bacterial artificial 
chromosome (BAC)-transgenic mice (88, 89). Regardless of the strategy, the promotor 
which drives Cre expression determines onset and cell type-specificity of the Cre-
mediated recombination. By crossing mice carrying a loxP-flanked mutation of the gene 
of interest with mice expressing the Cre recombinase restricted to specific tissues, a 
conditional mouse mutant is generated that lacks the target gene only in the cells in 
which Cre is expressed. 
To analyze gene function at a certain developmental stage, Cre expression can 
be temporally controlled either in a transcriptional or in a post-translational manner (for 
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review see (90)). Post-translational control of Cre expression involves the use of steroid 
hormone receptors. In the absence of their respective hormone ligands, these 
intracellular receptors are retained in the cytoplasm by the heatshock protein hsp90 (91). 
Binding of the respective hormones to the ligand binding domain (LBD) of the receptor 
leads to a conformational change, resulting in the dissociation of the multiprotein 
complex, thereby unmasking a nuclear localization sequence (NLS) which leads to the 
nuclear import of the receptor. In the nucleus, the receptor homodimerizes and binds 
specific hormone response elements (HRE) in the promoter of the target genes, thus 
either activating or repressing their transcription (92-94).  
Temporally controlled Cre expression can be achieved by fusing the Cre 
recombinase to the mutated LBD of a steroid hormone receptor. This fusion protein can 
be expressed from any cell type-specific promoter. Mutations in the LBD prevent 
binding and activation of the fusion protein by endogenous steroids (95-97). Upon 
binding of a synthetic ligand specific for the mutated ligand binding domain of the 
CreLBD fusion protein, heatshock proteins detach and the fusion protein is transported 
into the nucleus, where the Cre recombinase mediates the deletion of all loxP-flanked 
alleles (Fig. 3) (for review see (98)). 
 
Fig. 3: General scheme of the ligand-activated CreLBD fusion protein.  
The CreLBD fusion protein is sequestered by heatshock protein hsp90 in the cytoplasm. Binding of a 
synthetic ligand (T) to the mutated LBD promotes dissociation of hsp90 and nuclear import of the fusion 
protein, where the Cre recombinase (Cre) mediates recombination of the loxP (triangle) sites flanking an 
exon (4) of the gene of interest. 
 
A mutant LBD of the human estrogen receptor (ER), ERT2, has been generated, 
containing three amino acid substitutions, resulting in the inability of the estrogen 
receptor to be activated by its endogenous ligand, 17-β-estradiol (E2). The result is a 10-
fold higher affinity to synthetic ligands, such as the estrogen antagonists tamoxifen or 4-
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hydroxy-tamoxifen, compared to former single mutants of the ER-LBD (99). Numerous 
transgenic mouse strains carrying a chimeric protein consisting of the Cre recombinase 
and the triple mutant ERT2 (CreERT2) have been generated. Cre activity can be 
modulated in these mice by per os (p.o.) or intraperitoneal (i.p.) administration of 
tamoxifen, resulting in the highly efficient recombination of loxP-flanked target genes 
either ubiquitously or restricted to specific tissues (100-103). One of these mouse 
strains uses the ubiquitously expressed Rosa26 locus to drive expression of the CreERT2 
fusion protein (RosaCreERT2). As previously described for the RosaCreERT2 mice, 
upon tamoxifen administration, recombination occurs with high efficiency only in 
peripheral tissues, due to a lower local concentration of tamoxifen in the brain (100).  
 
1.5 RNA interference 
RNA interference (RNAi) is based on gene silencing using doublestranded RNA 
(dsRNA) (104). RNAi is mediated by short interfering RNAs (siRNAs), consisting of 
two 21 nucleotide single-stranded RNAs that form a 19 bp duplex with a 2 nucleotide 
3’overhang on each strand (105). dsRNA is cleaved by the enzyme Dicer to form 
siRNAs (106). Dicer is a highly conserved protein, consisting of two RNAse III 
domains, a double-stranded RNA binding domain and a long N-terminal region 
containing a DEAD-Box RNA helicase domain and a Piwi Argonaute Zwille (PAZ) 
domain (106-108). The PAZ domain has been shown to bind the 3’ overhang of small 
RNA molecules (109, 110). One protein family, after which the PAZ domain was 
named, consists of the Argonaute proteins. These are, together with Dicer, part of the 
RNA-induced silencing complex (RISC), which binds the antisense strand of the siRNA 
and uses it to guide mRNA cleavage, resulting in mRNA degradation (111) (Fig. 4). 
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Fig. 4: RNA interference.  
dsRNA is cleaved by Dicer into siRNAs. These bind to RISC and mediate mRNA degradation (adapted 
from (112)). 
 
1.5.1 Small hairpin RNAs 
In mammals, injection of long dsRNA to induce gene silencing leads to the 
activation of an antiviral response, resulting in translational repression and apoptosis in 
somatic cells (113, 114). These nonspecific dsRNA responses can be prevented by 
creating dsRNA triggers of less than 30 bp. In vivo expression constructs have been 
developed for so-called short hairpin RNAs (shRNAs), which resemble endogenously 
expressed hairpin RNAs and mediate sequence-specific gene silencing in mammalian 
cells without activating antiviral responses (115, 116). This approach uses small 
inverted repeats of 19 – 29 nt expressed under the control of an RNA polymerase III 
promoter to create shRNAs that are then processed by Dicer and shunted into the RNAi 
pathway. Conditional shRNA-mediated gene silencing in mice has been achieved by 
employing the Cre/loxP-System to induce tissue-specific control of shRNA expression 
(117-119). Temporal modulation of ubiquitous shRNA expression has been 
demonstrated in mice expressing a shRNA against the mRNA of the insulin receptor 
under the control of a modified RNA polymerase III-dependent promoter containing 
operator sequences from the E. coli tetracycline resistance operon from the ubiquitously 
expressed Rosa26 locus (120). 
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1.6 Mouse Mutants of Insulin and IGF-1 Receptor Signaling  
 Many insights into the molecular mechanisms of insulin action and its role in 
individual tissues of the mammalian organism have been gained from the in vivo 
inactivation of genes pivotal for insulin action, such as insulin, the insulin receptor, as 
well as downstream signaling molecules such as the IRS proteins, Gab-1, glucose 
transporter (GLUT)-2 and -4 and metabolic effector molecules like glucokinase (GK). 
Genes encoding insulin- like growth factors (IGF-1 and IGF-2) and their type I receptor 
(IGF-1R) have also been disrupted. A brief summary of the phenotypes is given in 
Table 1.  
 
Mutation Viable DM Phenotype Reference 
Insulin - + intrauterine growth retardation, death within 2 days of diabetic ketoacidosis and liver steatosis (121) 
IR - + normal intrauterine growth and development, death within 3 days of diabetic ketoacidosis (122) 
IRS-1 + - 
insulin resistance, hypertension, 
hypertriglyceridemia, 
impaired vascular relaxation 
(123-125) 
IRS-2 + + intrauterine and postnatal growth retardation (126) 
IRS-3 + n.d. normal glucose tolerance and growth (127) 
IRS-4 + - mild defects in growth, reproduction and glucose homeostasis  (128) 
Gab-1 - - intrauterine death,  developmental defects in heart, placenta, and skin (129) 
LGKO + - improved hepatic insulin sensitivity, reduced glycemia, improved glucose tolerance (130) 
βIRKO + + impaired insulin secretion (131) 
FIRKO + + 
reduced fat mass, protection against obesity and 
glucose intolerance, altered adipose tissue 
morphology 
(132) 
MIRKO + - increased adiposity (133) 
NIRKO + - normal brain development, mild insulin resistance,  diet-sensitive obesity (134) 
LIRKO + + progressive liver failure (135) 
IRS-1, GK + + growth retardation (136) 
FoxO1, IRS-
1 + - improved insulin sensitivity (137) 
GLUT-2 - mild death within 2-3 weeks, postnatal growth retardation (138) 
GLUT-4 + - reduced fat mass, growth retardation, mild impairment of glucose homeostasis (139) 
IR, IRS-1 + + hyperinsulinemia, β cell hyperplasia (140) 
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IGF-1 +/- - viability depends on background, dwarfism (141, 142) 
IGF-1R - - 
death within 2-3 hours of respiratory failure, 
dwarfism, developmental defects of skin, bone, 
CNS 
(141, 143) 
 
Table 1: Excerpt of transgenic and knockout mouse models involving genes of the insulin or IGF-1 
receptor signaling pathway.  
DM = Diabetes mellitus, n.d. = not determined, IR = insulin receptor, IRS = insulin receptor substrate, 
KO = knockout, β = β cell-specific, F = fat-specific, M = muscle-specific, N = neuron-specific, L = liver-
specific, G = Gab-1, GK = Glucokinase, FoxO1 = Forkhead transcription factor O1, GLUT = Glucose 
transporter, IGF = insulin-like growth factor. 
 
Most signaling molecules downstream of the insulin receptor exist in more than 
one isoform, such as Akt or Pdk, or can be composed of different subunits, like PI3K, 
rendering the inactivation of these proteins difficult. Consequently, a prominent amount 
of studies have focused on the inactivation of the insulin receptor gene in mice, either in 
a conventional fashion (122, 144) or by conditional inactivation of the insulin receptor 
in selected murine tissues (131-134, 145). These experiments have yielded unexpected 
findings with respect to the role of insulin action in classical insulin target tissues such 
as skeletal muscle, liver and adipose tissue (132, 133, 135), but also in tissues 
previously viewed as non-insulin responsive, such as brain, pancreatic β cells, 
macrophages and blood vessels (131, 134, 146, 147). Nevertheless, analyses of tissue- 
or cell type-specific insulin receptor knockout mice are limited by the lack of insulin 
receptor throughout development. Abnormalities arising from impaired insulin action 
can therefore be partly compensated for by adaptive processes or arise from 
developmental defects influencing the differentiation of respective tissues. 
 
1.7 Insulin and IGF-1 Receptor Signaling Redundancy 
The insulin receptor and the IGF-1 receptor are present on the surface of almost 
all cells, although their relative proportion varies depending on the target tissue. 
Although these two receptors represent two separate gene products, they exhibit up to 
85% homology in their amino acid sequence in different domains. Thus, while both 
insulin and IGF-1 exhibit the highest affinity to their innate receptors, insulin can also 
bind to and activate the IGF-1 receptor and IGF-1 is capable of binding to and 
activating the insulin receptor (for review see (148)). After binding of the ligand to its 
receptor, the same intracellular mechanisms modulate the activation of the PI3K or 
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MAPK signaling pathways (for review see (149)). Moreover, both receptors can form 
heterodimers, capable of effectively initiating the downstream signaling machinery 
(150, 151). Both the ligand binding characteristics as well as the formation of hybrid 
receptors raise the question of a possible redundancy between the two receptor tyrosine 
kinases. 
In experiments using insulin receptor-deficient hepatocytes, no metabolic effects, 
such as an increase in glycogen synthesis or inhibition of glucose production, could be 
detected  after insulin stimulation, whereas phosphorylation of insulin receptor 
substrates IRS-1 and Gab-1 and their binding of the PI3K was unaffected due to a 
compensatory activation via binding of insulin to the IGF-1 receptor (152). Also, the 
stimulation of muscle cells and fibroblasts of insulin receptor-deficient mice with IGF-1 
or high concentrations of insulin results in an increase in glucose uptake, glycogen 
synthesis, IRS-1 phosphorylation and activation of PI3K and MAPK (153, 154). These 
experiments clearly indicate the ability of the IGF-1 receptor to function as an 
alternative receptor to the insulin receptor in the metabolic signal transduction of insulin 
receptor-deficient muscle cells. The IGF-1 receptor-stimulated glucose uptake into the 
skeletal muscle is also partially responsible for the hypoglycemic effect detectable after 
injection of insulin receptor-deficient mice with IGF-1 (155). Mice with a muscle-
specific inactivation of the insulin receptor (MIRKO) maintain euglycemia with normal 
plasma insulin concentrations over months (133), indicating that a 95% reduction in 
insulin receptor protein and the resulting insulin resistance can be almost completely 
compensated for in MIRKO mice. Another example of IGF-1 receptor-mediated 
compensation for insulin receptor deficiency is provided by transgenic mice expressing 
a dominant-negative IGF-1 receptor in skeletal muscle. Transgene expression results in 
the formation of hybrid receptors between the mutant IGF-1 receptor and the 
endogenous IGF-1 and insulin receptor, leading to the inactivation of the endogenous 
receptors. This leads to insulin resistance and pancreatic β cell dysfunction, resulting in 
a diabetes-like phenotype (156). 
In conclusion, increasing evidence suggests an important role for the IGF-1 
receptor in insulin action, thus defining its signaling pathway as a possible candidate for 
the development of insulin resistance in the pathogenesis of Diabetes mellitus. 
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1.7.1 Insulin and IGF-1 Signaling in the CNS 
 Both the insulin receptor and the IGF-1 receptor are widely expressed throughout 
the central nervous system, both on neurons and glia cells (157, 158). Data from 
cultured neurons as well as animals lacking the insulin receptor or IGF-1 have 
established a role for the insulin/IGF-1 signaling machinery in the regulation of 
neuronal survival (159-162). 
 Insulin and IGF-1 have been demonstrated to regulate phosphorylation of the 
microtubule associated protein Tau. Hyperphosphorylated Tau represents a hallmark of 
neurodegenerative diseases such as Alzheimer’s disease (AD) as it constitutes the major 
protein of neurofibrillary tangles (for review see (163)). Moreover, increasing evidence 
indicates a direct effect of insulin and IGF-1 on the metabolism and clearance of β-
amyloid (Aβ) (164, 165), the deposition of which leads to the formation of neuritic 
plaques, a second key player in the pathogenesis of AD. Along this line, it could be 
demonstrated that IGF-1 treatment rescues neuronal apoptosis caused by a mutant form 
of the amyloid precursor protein (166). Mice with neuron-specific deletion of the 
insulin receptor gene exhibit hyperphosphorylation of Tau, presumably due to reduced 
activity of the AKT serine threonine kinase, resulting in disinhibition of glycogen 
synthase kinase (GSK)-3β, a well-characterized Tau kinase (160). Nevertheless, brain-
specific insulin receptor knockout mice fail to develop progression towards overt 
neurodegeneration and impaired learning.  
 Clinically, epidemiological studies clearly indicate the link of systemic insulin 
resistance, type 2 diabetes mellitus and AD. Therefore, neuronal insulin resistance 
might represent a risk factor, resulting in at least one of the biochemical hallmarks of 
Alzheimer’s disease. On the other hand, given the ability of insulin to bind to the IGF-1 
receptor and unaltered IGF-1 receptor signaling in brain-specific insulin receptor 
knockout mice, these experiments have left the question unaddressed, whether or not 
IGF-1 receptor signaling provides a compensatory mechanism in the presence of brain-
specific deletion of the insulin receptor gene. 
 Beside the regulation of neuronal growth and survival, insulin has been 
demonstrated to modulate energy homeostasis, presumably through its signaling in the 
hypothalamus, particularly in the arcuate nucleus of the hypothalamus (for review see 
(167)). Mice with brain-specific deletion of the insulin receptor exhibit an increased 
bodyweight (134). Nevertheless, the contribution of neuronal IGF-1 receptor signaling 
in the regulation of these processes has so far not been analyzed.  
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 In conclusion, there is strong evidence for the contribution of insulin and IGF-1 
signaling in the regulation of neuronal growth and survival as well as the regulation of 
food intake and peripheral glucose metabolism. The proposed analysis of IGF-1 
receptor signaling in mediating these effects will therefore reveal novel insights into the 
pathogenesis of neurodegenerative diseases as well as obesity and type 2 diabetes 
mellitus. 
 
1.7.2 IGF-1 Signaling in Learning and Memory Formation 
Many clinical syndromes including Alzheimer’s disease, semantic dementia, 
schizophrenia or cerebral trauma, among others, are associated with disorders of 
learning and memory. One of the major structures involved in learning and memory 
formation is the hippocampus. It is required for the formation of declarative memory, 
meaning facts or events that can be consciously verbalized, as well as spatial memory, 
which is responsible for retaining information on surroundings and spatial orientation.  
The integrity of the hippocampus has been shown to decline with age (168, 169). 
More frequent and more intense stimuli are then required to induce long-term 
potentiation (LTP), the molecular basis of memory formation. Cognitive deficits arising 
with old age appear to be the result of dysfunctions in neuronal circuits and synaptic 
plasticity, whereas neuronal cell death is apparently not influenced. 
Throughout adulthood, new neurons are continuously generated in the brain, 
specifically in the subventricular zone and the dentate gyrus of the hippocampus (for 
review see (170)). Hippocampal neurogenesis can be modulated by various factors 
including hormones, neurotransmitters or environment (171) and, like memory 
formation, has been demonstrated to decline with age (172). Several studies have linked 
neurogenesis with the formation of some types of hippocampus-dependent memories 
(173). IGF-1 has been implicated in synaptic plasticity and neurogenesis and, like 
memory formation and adult neurogenesis, is downregulated in an age-dependent 
manner (for review see (174)). Intracerebroventricular infusion of IGF-1 in aging 
animals ameliorates the decline in neurogenesis observed with senescence (175). In line 
with these studies, Ames dwarf mice, which display increased hippocampal IGF-1 
protein expression, live longer than normal animals and do not suffer from age-induced 
decline in cognitive function (176), revealing IGF-1 as a promising candidate in the 
regulation of conventional hippocampal neurogenesis. 
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1.8 Objectives 
To study central insulin action and insulin resistance in the pathogenesis of type 
2 diabetes mellitus in adult mice and to circumvent the problem of compensatory 
changes in the presence of insulin resistance during development, we opted for a time-
controlled approach to gene inactivation. To this end, mice were generated with an 
inducible whole body insulin receptor deficiency and an inducible insulin receptor 
knockout restricted to peripheral tissues of adult mice. The comparison of the 
phenotypes of both models allows the observation of consequences of acutely induced 
insulin resistance for the first time in adult mice and serves as a model for discerning 
the effects of peripheral versus whole body insulin resistance in the adult mouse. 
An additional aim of the current project was to address the contribution of the 
insulin-like growth factor 1 receptor signaling in the regulation of energy homeostasis 
and peripheral glucose metabolism, neuronal survival and learning and memory 
formation by generating and analyzing mice with a neuron-specific inactivation of the 
IGF-1 receptor gene by conditional mutagenesis. 
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2 Material and Methods 
2.1 Chemicals 
 Size markers for agarose gel electrophoresis (Gene Ruler DNA Ladder Mix) and 
for SDS-PAGE (Prestained Protein Ladder Mix) were obtained from MBI Fermentas, 
St. Leon-Rot, Germany. RedTaq DNA Polymerase and 10 x RedTaq buffer were 
purchased from Sigma-Aldrich, Seelze, Germany. 
 
Chemical Supplier 
α-[32P]-dCTP Amersham, Freiburg, Germany 
ε-aminocaproic acid Sigma-Aldrich, Seelze, Germany 
2-Deoxy-D-[1-14C]-Glucose Amersham, Freiburg, Germany 
Acetone KMF Laborchemie, Lohmar, Germany 
Acrylamide Roth, Karlsruhe, Germany 
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany 
Amyloglucosidase Roche, Mannheim, Germany 
Aprotinin Sigma-Aldrich, Seelze, Germany 
Benzamidine Sigma-Aldrich, Seelze, Germany 
β-Mercaptoethanol (β-ME) AppliChem, Darmstadt, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany 
Bradford reagent Bio-Rad, Munich, Germany 
Bromphenol blue Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
D-[3-3H]-Glucose Amersham, Freiburg, Germany 
Desoxy-Ribonucleotid-Triphosphates (dNTPs) Amersham, Freiburg, Germany 
Dextran sulfate AppliChem, Darmstadt, Germany 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Boehringer, Mannheim, Germany 
Doxycycline Hyclate Sigma-Aldrich, Seelze, Germany 
Enhanced Chemiluminscence (ECL) Kit Perbio Science, Bonn, Germany 
Ethanol, absolute AppliChem, Darmstadt, Germany 
Ethidium bromide Sigma-Aldrich, Seelze, Germany 
Ethylendiamine tetraacetate (EDTA) AppliChem, Darmstadt, Germany 
Fetal Calf Serum (FCS) Gibco BRL, Eggenstein, Germany 
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Ganciclovir Sigma-Aldrich, Seelze, Germany 
Gelatine Sigma-Aldrich, Seelze, Germany 
Geneticin (G418) Gibco BRL, Eggenstein, Germany 
Glacial acetic acid Roth, Karlsruhe, Germany 
Glucose DeltaSelect, Pfullingen, Germany 
Glycerol Serva, Heidelberg, Germany 
Hydrochloric acid (37 %) KMF Laborchemie, Lohmar, Germany 
Insulin Novo Nordisk, Bagsværd, Denmark 
Isopropanol Roth, Karlsruhe, Germany 
LaddermanTM DNA Labeling Kit Cambrex Bio Science, Verviers, Belgium 
Leptin Sigma-Aldrich, Seelze, Germany 
Methanol Roth, Karlsruhe, Germany 
Non-essential amino acids Gibco BRL, Eggenstein, Germany 
Penicillin/Streptomycin Solution Gibco BRL, Eggenstein, Germany 
Phenol-Chloroform-Isoamyl alcohol AppliChem, Darmstadt, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany 
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany 
Potassium hydroxide Merck, Darmstadt, Germany 
Proteinase K Roche, Mannheim, Germany 
RPMI 1640 w/out phenol red Gibco BRL, Eggenstein, Germany 
Salmon sperm DNA Sigma-Aldrich, Seelze, Germany 
Sodium acetate AppliChem, Darmstadt, Germany 
Sodium chloride AppliChem, Darmstadt, Germany 
Sodium dodecyl sulfate AppliChem, Darmstadt, Germany 
Sodium hydroxide AppliChem, Darmstadt, Germany 
Sodium fluoride Merck, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany 
Sodium pyruvate Gibco BRL, Eggenstein, Germany 
Sucrose AppliChem, Darmstadt, Germany 
Tamoxifen Sigma-Aldrich, Seelze, Germany 
Tetramethylethylenediamine Sigma-Aldrich, Seelze, Germany 
Avertin Sigma-Aldrich, Seelze, Germany 
Trishydroxymethylaminomethane (Tris) AppliChem, Darmstadt, Germany 
Triton X-100 Applichem, Darmstadt, Germany 
Tween 20 Applichem, Darmstadt, Germany 
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Western Blocking Reagent Roche, Mannheim, Germany 
 
Table 2: Chemicals 
 
2.2 Molecular Biology 
Standard methods of molecular biology were performed according to Sambrook 
and Russell (177), unless stated otherwise. 
 
2.2.1 Isolation of Genomic DNA 
 Mouse tail biopsies were incubated 1 hour (h) in lysis buffer (100 mM Tris-HCl 
(pH 8.5), 5 mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl, 500 mg/ml proteinase K) in a 
thermomixer (Eppendorf, Hamburg, Germany) at 56°C. Embryonic stem (ES) cells 
were incubated in lysis buffer at 60°C over night. DNA was then precipitated from the 
solution by adding an equivalent of isopropanol. After centrifugation, the DNA pellet 
was dried at 60°C for 10 minutes and resuspended in doubly distilled water (ddH2O).  
 For Southern blot analysis, 100 mg of murine tissue DNA were digested in lysis 
buffer containing 1 g/ml of proteinase K over night in a thermomixer at 56°C. Samples 
were centrifuged to discard debris and an equal volume of phenol-chloroform-isoamyl 
alcohol mixture ((v/v/v) 25:24:1, saturated with 100 mM Tris (pH 8.0)) was added to 
the supernatant. Following centrifugation, the aqueous phase was transferred to a fresh 
vial and mixed with an equivalent of chloroform. After centrifugation, DNA was 
precipitated from the supernatant as described above and resuspended in TE buffer (10 
mM Tris-HCl (pH 8), 1 mM EDTA) containing 50 µg/ml RNAseI. 
 
2.2.2 Quantification of Nucleic Acids 
 DNA and RNA concentrations were assessed by measuring the sample 
absorption at 260 nm with a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Peqlab, 
Erlangen, Germany). An optical density of 1 corresponds to approximately 50 µg/ml of 
double-stranded DNA and to 38 µg/ml of RNA. 
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2.2.3 Polymerase Chain Reaction (PCR) 
 The PCR method (178, 179) was used to genotype mice for the presence of 
floxed alleles or transgenes with customized primers listed in Table 3. Reactions were 
performed in a Thermocycler iCycler PCR machine (Bio-Rad, Munich, Germany) or in 
a Peltier Thermal Cycler PTC-200 (MJ Research, Waltham, USA). All amplifications 
were performed in a total reaction volume of 25 µl, containing a minimum of 50 ng 
template DNA, 25 pmol of each primer, 25 µM dNTP Mix, 10 x RedTaq reaction buffer 
and 1 unit of RedTaq DNA Polymerase. Standard PCR programs started with 4 minutes 
(min) denaturation at 95°C, followed by 30 cycles consisting of denaturation at 95°C for 
45 seconds (sec), annealing at oligonucleotide-specific temperatures for 30 sec and 
elongation at 72°C for 30 sec and a final elongation step at 72°C for 7 min.  
 
Primer Sequence (5’-3’) TAnnealing [°C] Orientation 
Cre5’ ACCTGAAGATGTTCGCGATTATCT 57 sense 
Cre3’ ACCGTCAGTACGTGAGATATCTT 57 antisense 
IR5’ GATGTGCACCCCATGTCTG 58 sense 
IR3’ CTGAATAGCTGAGACCACAG 58 antisense 
shRNA5’ CCATGGAATTCGAACGCTGACGTC 60 sense 
shRNA3’ TATGGGCTATGAACTAATGACCC 60 antisense 
IGF1R5' TCC CTC AGG CTT CAT CCG CAA 59 sense 
IGF1R3' CTT CAG CTT TGC AGG TGC ACG 59 antisense 
 
Table 3: Oligonucleotides used for genotyping.  
All primer sequences are displayed in 5’-3’ order. Primer orientation is designated “sense” when 
coinciding with transcriptional direction. All primers were purchased from Eurogentec, Cologne, 
Germany. 
 
PCR-amplified DNA fragments were applied to 1% - 3% (w/v) agarose gels (1 x 
TAE, 0.5 mg/ml ethidium bromide) and electrophoresed at 120 V. 
 
2.2.4 Southern Blot Analysis 
 10 µg of phenol-chloroform-extracted DNA were digested over night at 37°C 
with 50 U of either NcoI or BamHI restriction enzyme (MBI Fermentas GmbH, St. 
Leon-Rot, Germany) and separated electrophoretically on a 0.8% agarose gel at 60 V. 
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The DNA was subsequently transferred to a HybondTM-N+ nylon membrane 
(Amersham, Braunschweig, Germany) by an alkaline capillary transfer (180) and 
crosslinked to the membrane by baking at 80°C for 20 min. A probe was PCR-amplified 
using customized primers (Table 4) and labelled with [32P]-dCTP using the 
LaddermanTM DNA Labeling Kit (TaKaRa; Cambrex Bio Science, Verviers, Belgium). 
Membranes were equilibrated in 2 x SSC and then prehybridized at 65°C over 4 h in 
hybridization solution (1 M NaCl, 1% (w/v) SDS, 10% (w/v) dextran sulfate, 50 mM 
Tris-HCl (pH 7.5), 250 µg/ml sonicated salmon sperm DNA). The radioactively labeled 
probe was then added to the prehybridization solution. Hybridization of the probe to its 
corresponding sequence on the nylon membrane was performed over night at 68°C in a 
rotating cylinder. Unspecifically bound probe was removed by washing the membrane 
initially with 2 x SSC / 0.1 % (w/v) SDS, followed by 1 x SSC / 0.1% (w/v) SDS, if 
necessary. All washes were performed at 68°C under gentle shaking for 10-20 min. 
After each wash, the membrane was monitored with a Geiger counter and the washes 
were stopped when radioactivity reached 50 to 200 cps. The membrane was then sealed 
in a plastic bag and exposed to X-ray film (Kodak XAR-5 or BioMAX MS; Eastman 
Kodak) at -80°C. Films were developed in an automatic developer (Agfa, Cologne, 
Germany). 
 
Probe Primer Sequence (5’-3’) Orientation 
IR NcoI5’ CCATGGGTCCATAAGCTATC sense 
IR NcoI3’ AGTGATGAGATGGCTCATTAG antisense 
IGF-1R BamHI5’ ACTTTGTGAGTTGAGCCACAG sense 
IGF-1R BamHI3’ ACATTATGTTTGCGCTGGGAA antisense 
 
Table 4: Oligonucleotides used to amplify the Southern blot probes.  
All primer sequences are displayed in 5’-3’ order. Primer orientation is designated “sense” when 
coinciding with transcriptional direction. All primers were purchased from Eurogentec, Cologne, 
Germany. 
 
2.2.5 RNA Extraction, RT PCR and Quantitative Realtime PCR 
 Total hepatic RNA was extracted using the Qiagen RNeasy Kit (Qiagen, Hilden, 
Germany). 200 ng of each RNA sample were reversely transcribed using the Eurogentec 
RT Kit (Eurogentec, Cologne, Germany) according to manufacturer’s protocols. The 
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cDNA was subsequently amplified using TaqMan Principles ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Foster City, USA). Relative expression of 
ObRb and IL-6 mRNA was determined using standard curves based on hepatic cDNA. 
Relative expression of LPL mRNA was determined using standard curves based on 
white adipose tissue cDNA. Samples were adjusted for total RNA content by 
Glucuronidase beta (Gusb) and hypoxanthine guanine phosphoribosyl transferase (Hprt-
) 1 RNA quantitative Realtime-PCR. Calculations were performed by a comparative 
method (2-δδCT). 
 
Probe Catalogue N° 
Gusb Mm00446953_m1 
Hprt-1 Mm00446968_m1 
ObRb Mm01265583_m1 
IL-6 Mm00446190_m1 
LPL Mm00434764_m1 
 
Table 5: Probes used for Realtime PCR.  
All probes were purchased from Applied Biosystems, Foster City, USA. 
 
2.2.6 ELISA 
 Mouse serum insulin (Mouse/Rat Insulin ELISA; Crystal Chem, Downers 
Grove, IL, USA), leptin (ACTIVE® Murine Leptin ELISA; Diagnostics Systems 
Laboratories, Webster, TX, USA) and adiponectin (Quantikine Mouse 
Adiponectin/Acrp30 ELISA; R&D Systems, Wiesbaden, Germany) concentrations were 
determined using mouse standards according to manufacturer’s guidelines and 
measured on a Precision Microplate Reader (Emax; Molecular Devices GmbH, Munich, 
Germany). 
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2.3 Cell Biology 
2.3.1 Gene Targeting and Generation of IGF-1RΔSyn Mice 
A targeting vector was constructed as previously described (181) by inserting a 
600 bp sequence containing exon 3 of the murine IGF-1 receptor gene into the gene 
replacement vector pEasyfloxGK12 (Artemis Pharmaceuticals, Cologne, Germany). A 
4.5 kbp sequence homologous to the target gene sequence upstream of exon 3 and a 1.3 
kbp gene sequence homologous to the downstream region of exon 3 were inserted to be 
used as long and short arm of homology, respectively. The vector was purified by 
agarose gel electrophoresis following NotI digestion to remove plasmid sequences prior 
to electroporation. 
Gene targeting was performed in Bruce4 ES cells (182). Culturing and 
transfection of ES cells was performed according to previously described protocols 
(181). For transfection, 1x107 ES cells were transfected with 40 µg DNA as previously 
described (133). 48 hours after transfection, ES cells were placed under selection with 
the neomycin-analog G418 (180 μg/ml, 71% active). G418 inhibits the 80S ribosome, 
thereby blocking protein synthesis. Integration of the neomycin resistance gene (neor) 
into the genome via recombination enables the ES cells to grow in G418-containing 
medium. To select against randomly integrated gene constructs that still contain the 
thymidine kinase cassette of the Herpes simplex virus (HSV-tk), the medium was 
supplemented with 2 mM ganciclovir 5 days after transfection. The HSV-tk gene lies 3’ 
of the short homology arm of the gene targeting vector and thus outside of the 
recombination region. Hence, it is only integrated into the genome upon non-
homologous recombination (183). HSV-tk phosphorylates ganciclovir, thereby 
converting it to a triphosphate which is inserted into the DNA instead of guanine, 
resulting in the disruption of DNA replication. Approximately 9 days after transfection, 
G418/Ganciclovir double-resistant colonies were picked and expanded on 96-well 
tissue culture dishes. Genomic DNA was extracted from each clone and analysed by 
Southern blot and PCR analysis. Recovery, microinjection and transfer of 3.5 day-old 
embryos were performed according to standard procedures. Chimeric animals (80-90% 
chimerism based on coat color) were bred with FlpE deleter on a pure C57BL/6 
background. 
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2.3.2 Histological Analysis and Immunohistochemistry 
 Pancreatic tissue of IRΔper and IRΔwb mice was excised and snap-frozen in Jung 
Tissue Freezing Medium® (Leica Microsystems Nussloch GmbH, Nussloch, Germany), 
transferred to a cryostat (Leica Microsystems Nussloch GmbH, Nussloch, Germany) 
and cut into 7 µm thin sections. Specimens were collected on clean poly-L-lysine-
coated glass slides (Menzel GmbH, Braunschweig, Germany), dried at room 
temperature overnight and then stained using hematoxylin and eosin (H&E) for general 
histology. H&E (Sigma-Aldrich, Seelze, Germany) staining was performed according to 
standard protocols. Pancreatic tissues were also stained for insulin (DakoCytomation, 
Hamburg, Germany) and glucagon (DakoCytomation, Hamburg, Germany) using a 1:20 
and 1:75 dilution, respectively. Slides had been previously fixed in acetone at 4°C for 
10 min and air-dried. Both stainings were incubated with a secondary antibody 
consisting of a 1:100 dilution of horseradish peroxidase-coupled anti-rabbit IgG (Vector 
Laboratories/Linaris GmbH, Wertheim-Bettingen, Germany). Tissues were 
counterstained 2 minutes with Mayers Hematoxylin then washed in tepid water for 5 
minutes. Stainings were analyzed with a Zeiss Axioskop 40 microscope (Carl Zeiss 
MicroImaging GmbH, Cologne, Germany) and β cell mass was determined using the 
microscopy software AxioVision (Carl Zeiss MicroImaging GmbH, Cologne, 
Germany). 
White adipose tissue of C57BL/6 mice was dissected, fixed overnight in 7% 
formaldehyde and then embedded for paraffin sections. Subsequently, 7 µm thin 
sections were deparaffinized and stained with H&E for general histology. 
 For staining against IGF-1 receptor and β-galactosidase, IGF-1RΔSyn mice were 
bred with RosaArte1 reporter mice (100). IGF-1RΔSyn-LacZ and wildtype reporter 
(SynCre-LacZ) mice were anesthetized and transcardially perfused with 0.9% saline 
solution. Brains were then excised and frozen in tissue freezing medium. 7 µm cryostat 
sections were stained with a 1:50 dilution of IGF-1Rα (Upstate, Billerica, USA) and a 
1:200 dilution of β-galactosidase antibody (Cappel, Cochranville, USA). The IGF-1R 
staining was subsequently incubated  with 1:500 dilution of a FITC-labeled goat anti-
chicken secondary antibody (Invitrogen, Karlsruhe, Germany). β-galactosidase 
stainings were stained with a 1:200 dilution of a multifluorescent anti-rabbit IgG 
(Mobitec GmbH, Göttingen, Germany). Slides were analyzed and photographed using a 
Zeiss Axioskop 40 microscope. 
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2.4 Biochemistry 
2.4.1 Protein Extraction 
 Snap-frozen tissues were thawed and homogenized in lysis buffer (50 mM 
HEPES (pH 7.4), 1% Triton X-100, 0.1 M sodium fluoride, 10 mM EDTA, 50 mM 
sodium chloride, 10 mM sodium orthovanadate, 0,1% SDS, 10 µg/ml Aprotinin, 2 mM 
Benzamidine, 2 mM PMSF) using a polytron homogenizer (IKA Werke, Staufen, 
Germany). Particulate matter was removed by centrifugation for 1 h at 4°C. The 
supernatant was transferred to a fresh vial and protein concentrations were determined 
using a Bradford assay. Protein extracts were diluted to 1 mg/ml with lysis buffer and 4 
x SDS sample buffer (125 mM Tris-HCl (pH 6.8), 5% SDS, 43.5% glycerol, 100 mM 
DTT, and 0.02% bromphenol blue), incubated at 95°C over 5 min and stored at -80°C.  
 
2.4.2 Western Blot Analysis 
 Frozen protein extracts were thawed at 95°C for 5 min, then separated on 8-10% 
(v/v) SDS polyacrylamide gels (184) and blotted onto PVDF membranes (Bio-Rad, 
Munich, Germany). Membranes were then incubated with 1% blocking reagent (Roche, 
Mannheim, Germany) for 1 h at RT or over night at 4°C. Subsequently, primary 
antibodies (Table 6) diluted in 0.5% blocking solution were applied for 1 h at RT or 
over night at 4°C. PVDF membranes were then washed twice for 10 min with 1 x 
TBS/Tween and incubated twice for 10 min with 0.5% blocking solution. After 1 h 
incubation at RT with the respective secondary antibodies, membranes were washed 4 
times for 5 min with 1 x TBS/Tween, incubated for 1 min in Pierce ECL Western 
Blotting Substrate (Perbio Science, Bonn, Germany), sealed in a plastic bag and 
exposed to chemiluminescence film (Amersham, Braunschweig, Germany) at -80°C. 
Films were developed in an automatic developer. 
 
Antibody Catalogue N° Distributor Dilution 
Akt #9272 Cell Signaling, Danvers, MA, USA 1:1000 
pAkt (Ser473) #9271 Cell Signaling, Danvers, MA, USA 1:1000 
IRβ (C-19) sc-711 Santa Cruz, Heidelberg, Germany 1:200 
ObR (M-18) sc-1834 Santa Cruz, Heidelberg, Germany 1:400 
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Stat-3 (C-20) sc-482 Santa Cruz, Heidelberg, Germany 1:400 
pStat-3 (B7) sc-8059 Santa Cruz, Heidelberg, Germany 1:200 
IGF-1Rβ #3027 Cell Signaling, Danvers, MA, USA 1:200 
Actin A5441 Sigma Aldrich, Seelze, Germany 1:2000 
 
Table 6: Primary antibodies used for Western blot analysis.  
All respective secondary antibodies were purchased from Sigma Aldrich, Seelze, Germany, and used in a 
1:1000 dilution. 
 
2.5 Mouse Experiments 
 General animal handling was performed as described by Hogan (185) and Silver 
(186). 
 
2.5.1 Animals 
 Mice were housed in a virus-free facility at 22-24°C on a 12 h light/ 12 h dark 
cycle with the light on at 6 a.m. and were fed standard rodent chow (Teklad Global 
Rodent 2018; Harlan Winkelmann GmbH, Borchen, Germany) containing 53.5% 
carbohydrates, 18.5% protein and 5.5% fat. All animals had access to water ad libitum. 
Food was only withdrawn if required for an experiment. At the end of the study period, 
animals were sacrificed by CO2 anesthesia or cervical dislocation. All animal 
procedures and euthanasia were reviewed by the animal care committee of the 
University of Cologne, approved by local government authorities (Bezirksregierung 
Cologne) and were in accordance with National Institutes of Health guidelines. 
 
2.5.1.1 IRΔper mice 
 Mice homozygous for the loxP-flanked insulin receptor allele (IRflox/flox) (133) 
were bred with mice heterozygous for the Rosa26CreERT2 transgene (100). 
Rosa26CreERT2+/-IRflox/wt mice were further crossed with IRflox/flox mice to achieve 
homozygosity for the loxP-flanked allele. Breeding colonies were maintained by mating 
IRflox/flox mice and Rosa26CreERT2+/-IRflox/flox mice (IRΔper). 
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2.5.1.2 IRΔwb mice 
 Breeding colonies were maintained for C57BL/6 mice and mice expressing an 
insulin receptor-specific shRNA from the Rosa26 locus (120). 
 
2.5.1.3 IGF-1RΔSyn mice 
A correctly integrated homologous recombinant ES cell clone was injected into 
a CB-20 blastocyst and implanted into the uterus of a pseudopregnant mouse. Resulting 
chimeras were crossed with C57BL/6 mice. IGF-1Rflox/wt mice, which had received the 
mutation by germline transmission, were crossed with FlpE deleter mice to insure 
deletion of the selection marker cassette. Intercrosses of IGF-1Rflox/wt mice yielded mice 
homozygous for the recombinant locus IGF-1Rflox/flox. IGF-1Rflox/flox were crossed with 
mice expressing the Cre recombinase under the control of the rat Synapsin-1 promoter 
(187) to delete the IGF-1 receptor specifically in neurons.  
 
2.5.2 Experimental Setup 
2.5.2.1 Tamoxifen administration 
 An aliquot of 50 mg tamoxifen-free base (Sigma Aldrich, Seelze, Germany) was 
suspended in 50 µl ethanol and dissolved in 500 µl peanut oil (Sigma Aldrich, Seelze, 
Germany). This 5 mg/50 µl tamoxifen solution was sonicated for 1 minute and then 
stored at -20°C. On five consecutive days at the age of 9-12 weeks, the tamoxifen 
solution was thawed at 60°C and administered to IRΔper mice by oral gavage using a 22 
gauge feeding needle (Fine Science Tools, Heidelberg, Germany). 
 
2.5.2.2 Doxycycline administration 
 At 10-13 weeks of age, IRΔwb mice were administered drinking water 
supplemented with 10% sucrose and 2 mg/ml doxycycline hyclate over a period of 30 
days to induce shRNA-expression under control of the H1/U6 promoter. Doxycycline-
supplemented water was changed every 2-3 days. 
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2.5.3 Body Weight and Blood Glucose Levels 
 Body weight and blood glucose levels were monitored daily. Blood glucose 
values were determined from whole venous blood using an automatic glucose monitor 
(GlucoMen® GlycÓ; A. Menarini Diagnostics, Neuss, Germany). 
 
2.5.4 Food Intake 
 Food Intake was measured over a period of 30 days and daily food intake was 
calculated as the average intake of chow over the time stated. 
 
2.5.5 Glucose and Insulin Tolerance Test 
 Glucose tolerance tests (GTT) were performed on animals that had been fasted 
over night for 16 hours. Insulin tolerance test (ITT) was performed on random fed mice. 
Animals were injected with either 2 g/kg body weight of glucose or 0.75 U/kg body 
weight of human regular insulin into the peritoneal cavity. Glucose levels were 
determined in blood collected from the tail tip immediately before and 15, 30 and 60 
minutes after the injection, with an additional value determined after 120 minutes for 
the GTT. 
 
2.5.6 Glucose-stimulated Insulin Secretion 
 All animals were fasted over night for 16 hours. Blood samples were collected 
from mice prior to an intravenous injection of 2g/kg body weight of glucose. Further 
blood samples were amassed 2, 5, 15, 30 and 60 min after the injection and serum 
insulin levels were determined.  
 
2.5.7 Insulin Signaling 
 Mice were anesthetized by intraperitoneal (i.p.) injection of avertin and 
adequacy of the anesthesia was ensured by loss of pedal reflexes. The abdominal cavity 
of the mice was opened and 125 µl samples containing 5 units regular human insulin 
diluted in 0.9% saline were injected into the Vena cava inferior. Sham injections were 
performed with 125 µl of 0.9% saline. Samples of liver tissue and skeletal muscle tissue 
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were harvested two and five minutes after injection, respectively. Proteins were 
extracted from tissues for Western blot analysis. 
 
2.5.8 Intracerebroventricular Insulin Infusion 
 For intracerebroventricular (icv) cannula implantation, 11-week old male 
C57BL/6 mice were anesthetized as previously described and placed in a stereotactic 
device (Stoelting, Foehr Medical Instruments GmbH, Seeheim, Germany). A sterile 
osmotic pump connector cannula (Alzet® Brain Infusion Kit 3, Charles River, Sulzfeld, 
Germany) was implanted into the left lateral brain ventricle (-0.2 mm anterior, 1.0 mm 
lateral relative to Bregma, 2.3 mm below the surface of the skull). The pedestal of the 
cannula was attached to the skull with super glue. The cannula was connected to an 
Alzet® mini-osmotic pump (Model 1002; Charles River, Sulzfeld, Germany), which 
secreted 200 µU insulin per day over a period of 7 days. After 7 days, animals were 
sacrificed and correct positioning of the icv cannula was verified in each animal by 
injection of 1% methylene blue. White adipose tissue mass was removed, weighed and 
processed for histological analysis and RNA extraction as described. 
 
2.5.9 Leptin Restoration 
 16 days after start of administration of doxycycline-supplemented water, 5 IRΔwb 
mice and 5 respective controls were anesthetized by i.p. avertin injection and 
subcutaneously implanted Alzet® mini-osmotic pumps (Model 2001; Charles River, 
Sulzfeld, Germany), which secrete 0.5 µg leptin per µl per h over a period of 7 days. 
Food intake, body weight and blood glucose were measured daily over the entire period 
of the experiment, starting two days prior to pump implant. Serum blood samples were 
taken 2, 4 and 7 days after the operation to monitor leptin levels. 7 days after pump 
implant, mice were sacrificed and hepatic Stat-3 phosphorylation was assessed by 
Western blot analysis. 
 
2.5.10 Kainic Acid-induced Seizures 
 To evaluate potential neurotoxicity caused by kainic acid, 16-week-old IGF-
1RΔSyn mice and littermate controls received an i.p. injection of 30 mg/kg kainic acid 
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(KA; Sigma Aldrich, Seelze, Germany) before noon, in order to minimize interactions 
with circadian patterns of endogenous substances such as hormones and 
neurotransmitters. KA-induced seizures were scored for 2 h post-injection based on the 
following criteria: 0 = no abnormality; 1 = mice become motionless; 2 = forelimb 
and/or tail extension (appearance of rigid posture); 3 = myoclonic jerks of head and 
neck, w/ brief twitching movements, or repetitive movements w/ head bobbing or "wet-
dog-shakes"; 4 = forelimb clonus and partial rearing or rearing and falling; 5 = forelimb 
clonus, continuous rearing and falling; 6 = generalized tonic-clonic activity w/ loss of 
postural tone, often resulting in death. Time of seizure initiation was measured from 
time of KA injection to more than or equal to stage 3. In addition, maximum seizure 
intensity and seizure scores at various time points were analyzed. 3 days after KA 
injection, mice were anesthetized with avertin and perfused intracardially with saline. 
Brains were removed and cut into 7 µm thin sections that were subjected to Nissl 
staining with 0.1% cresyl violet (Sigma Aldrich, Seelze, Germany) for assessment of 
neuronal damage. Slides were analyzed and photographed using a Zeiss Axioskop 40 
microscope. 
 
2.5.11 Analysis of Body Composition 
 Nuclear magnetic resonance (NMR) was employed to determine whole body 
composition of live animals using the NMR Analyzer minispec mq7.5 (Bruker Optik, 
Ettlingen, Germany). Radiofrequency (RF) pulse sequences are transmitted into the 
tissue. In response, RF signals are generated by the hydrogen in the tissue, which are 
detected by the minispec. The amplitude and duration of these signals are related to 
properties of the material. 
 
2.5.12 Behavioral Analysis 
2.5.12.1 Morris Water Maze 
This test was performed according to standard procedures (188) with minor 
modifications previously described (189, 190). In summary, after a 1 day habituation 
trial (day 0), in which preferences of IGF-1RΔSyn mice and littermate controls for a 
specific quadrant were ruled out, the animals learned to find a hidden platform over the 
following 6 days, performing 4 trials per day, each trial lasting 60 seconds plus 20 
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seconds on the platform. If an animal failed to reach the platform, it was placed on it 
after 60 seconds. On the 7th day, the animals were subjected to an extinction trial, in 
which the platform had been removed to assess preference for the platform quadrant. 
 
2.5.12.2 Rotarod 
Motor coordination of IGF-1RΔSyn mice and littermate controls was determined by 
placing the animals in a rotarod apparatus with constant acceleration in 6 consecutive 
trials of 5 minutes each (191). The apparatus consisted of a horizontal motor-driven 
rotating rod in which the animals were placed perpendicular to the long axis of the rod, 
with the head directed against the direction of rotation so that the mouse has to progress 
forward to avoid falling. Animals were familiarized with the procedure under constant 
rod speed 1 day earlier. The trial was stopped when the animal fell down or after a 
maximum of 5 min. The time spent in the rotating rod was recorded for each animal and 
trial. 
 
2.5.12.3 Elevated Plus-Maze 
IGF-1RΔSyn mice and littermate controls were exposed to an elevated plus-maze, 
consisting of two open and two enclosed arms, to study anxiety-like behavior (192, 
193). Each rat was placed on the central platform facing a closed arm, and allowed to 
freely explore the maze for 5 min. Exploration was recorded through an automated 
tracking system. Percentage of time spent exploring the open arms were calculated as an 
index of anxiety-like behavior. 
 
2.5.12.4 Object Recognition 
IGF-1RΔSyn mice and littermate controls were individually habituated to an open-
field box for 3 days. During training sessions, two novel objects were placed into the 
open field and the animal was allowed to explore for 5 min. The time spent exploring 
each object was recorded. During retention tests, the animals were placed back into the 
same box, in which one of the familiar objects used during training was replaced by a 
novel object, and allowed to explore freely for 5 min. A preference index was 
determined from the amount of time spent exploring the novel object over the total time 
spent exploring both objects to measure visual recognition memory. 
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2.5.12.5 Activity Cage 
Exploratory activity levels were determined using photocell detection, based on 
a computer-based system which registers an animal’s horizontal and vertical 
movements within a plexiglas box equipped with ultrared beams. Activity was defined 
as the interruption of a photocell beam and the number of interruptions was recorded.  
 
2.6 Computer Analysis 
2.6.1 Densitometrical Analysis 
 Protein expression was assessed by Western blot analysis and bands were 
measured in intensity per mm2 using the Quantity One Software (Bio-Rad, Munich, 
Germany). After background subtraction, each sample was normalized to an internal 
loading control. Average protein expression of control mice was set to 100% and 
compared to protein expression of knockout animals unless stated otherwise. 
 
2.6.2 Statistical Methods 
 Data sets were analyzed for statistical significance using a two-tailed unpaired 
student’s t test. All p values below 0.05 were considered significant. 
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3 Results 
3.1 Inducible inactivation of the insulin receptor gene in 
peripheral tissues of adult mice 
 Mice homozygous for the loxP-flanked insulin receptor allele (IRflox/flox) were 
crossed with mice expressing a Cre recombinase fused to the mutated ligand binding 
domain of the estrogen receptor from the ubiquitous Rosa26 locus (Rosa26CreERT2) 
(Fig. 5). The Cre recombinase is inactive as long as it is retained in the cytoplasm by 
heatshock proteins. Administration of tamoxifen results in the detachment of the 
heatshock proteins, thereby uncovering a nuclear localization signal that leads to the 
nuclear import of the fusion protein. In the nucleus, Cre mediates recombination of all 
loxP-flanked alleles. When expressed from the Rosa26 locus, Cre-mediated 
recombination of loxP-flanked alleles occurs in all tissues except the central nervous 
system, due to a lower local concentration of tamoxifen in the brain (103, 194). 
 
Fig. 5: General scheme of the inducible peripheral insulin receptor knockout mouse (IRΔper).  
Mice, expressing the CreERT2 fusion protein under the control of the Rosa26 promoter (Rosa26CreERT2) 
were crossed with mice homozygous for a loxP-flanked exon 4 of the insulin receptor allele (IRflox/flox). 
Only one loxP-flanked allele is depicted here. Each loxP site is here and hereafter depicted as a triangle. 
 
To inactivate the insulin receptor gene in peripheral tissues of adult mice in an 
inducible manner and to control for the metabolic effects of tamoxifen treatment, IRΔper 
and IRflox/flox Rosa26CreERT2-negative littermates (ControlΔper) were treated daily by 
oral administrations of 5 mg tamoxifen on 5 consecutive days. At various time points 
during and after the feeding period, tissues were removed from the animals and 
recombination of the loxP-flanked insulin receptor gene was assessed by Southern blot 
analysis (Fig. 6, Fig. 7). Just two days after the start of tamoxifen administration, partial 
recombination of the loxP-flanked insulin receptor gene was detectable in heart, skeletal 
muscle, liver, pancreas and white adipose tissue of IRΔper mice. Recombination was 
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almost complete on the first day after the last feeding (day 6) (Fig. 7). While deletion 
was variable in heart, ranging between 70 and 80%, more than 90% of the recombined 
loxP-flanked insulin receptor gene was detectable in skeletal muscle and liver. The most 
efficient recombination occurred in pancreas and white adipose tissue (Fig. 7), while, as 
expected, less than 15% recombination was found in the CNS. 
 
 
Fig. 6: Genomic map of the mouse insulin receptor locus surrounding exon 4.  
Location of the probe used for Southern blot analysis is indicated by a black bar. NcoI = restriction 
enzyme sites, 4 = exon 4 of the insulin receptor gene, 2.5 kb = size of loxP-flanked allele band, 5 kb = 
size of deleted allele band. 
 
 
 
 
Fig. 7: Southern blot analysis of insulin receptor recombination.  
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Tissues analyzed were whole brain, heart, skeletal muscle, liver, pancreas and white adipose tissue 
(WAT) of IRΔper mice over a period of 12 days. Mice were administered tamoxifen from day 1 until day 
5. Δ = 5 kb band of the deleted allele, flox = 2.5 kb band of the loxP-flanked allele. 
 
 In conclusion, efficient tamoxifen-induced recombination of the loxP-flanked 
insulin receptor alleles in IRΔper mice was achieved in metabolically relevant peripheral 
tissues such as heart, skeletal muscle, liver, pancreas and white adipose tissue without 
significant recombination occurring in the CNS. 
 To investigate the impact of Cre-mediated recombination on insulin receptor 
protein expression, Western blot analyses were performed on tissue lysates obtained 
from IRΔper mice during and after tamoxifen treatment. As expected, the level of 
immunoreactive insulin receptor protein paralleled that of the loxP-flanked insulin 
receptor allele recombination (Fig. 8). Hence, while there was a visible decline of 
insulin receptor expression in heart and skeletal muscle over the course of 24 days after 
the beginning of tamoxifen administration, the maximum reduction of insulin receptor 
expression observed on day 30 was approximately 50% in the former and 90% in the 
latter, consistent with the presence of unrecombined loxP-flanked insulin receptor 
alleles in these tissues (Fig. 8). Similarly, insulin receptor protein expression was 
abolished in liver, pancreas and white adipose tissue of IRΔper mice after completion of 
tamoxifen treatment (Fig. 9), whereas protein extracts prepared from whole brain 
revealed no alteration in immunodetectable insulin receptor protein (Fig. 8). 
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Fig. 8: Western blot analysis of insulin receptor expression.  
Western blot analysis of insulin receptor (IR) and proteinkinase B (AKT, loading control) expression. 
Proteins were extracted form whole brain, heart, skeletal muscle, liver, pancreas and WAT of tamoxifen-
treated IRΔper mice and ControlΔper mice over a period of 24 days. Tamoxifen administration lasted from 
day 1 until day 5. 
 
 To rule out the possibility that the modest amount of Cre-mediated 
recombination detectable in whole brain extracts of IRΔper mice (Fig. 7) was due to 
complete recombination in a certain area of the brain rather than a modest degree of 
recombination throughout, individual brain regions were probed for immunodetectable 
insulin receptor protein. This analysis revealed unaltered insulin receptor expression in 
hypothalamus, cortex and cerebellum of tamoxifen-treated IRΔper mice (Fig. 9). Thus, 
consistent with the pattern of DNA recombination, insulin receptor protein expression 
was efficiently reduced in peripheral tissues of IRΔper mice without significant 
alterations in the CNS. 
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Fig. 9: Insulin receptor deficiency in peripheral organs of IRΔper mice.  
(A) Western blot analysis of insulin receptor (IR) and proteinkinase B (AKT, loading control) expression 
in whole brain, hypothalamus, cortex, cerebellum, heart, skeletal muscle, liver and pancreas of tamoxifen-
treated ControlΔper and IRΔper mice. Indicated tissues were dissected 25 days after the last day of tamoxifen 
administration. (B) Relative IR expression of ControlΔper (black bars) and IRΔper mice (white bars) as 
assessed by Western blot analysis. Values are mean ± SEM. *P ≤ 0.05; **P ≤ 0.01 versus control. 
 
 Next, insulin’s ability to activate signaling in skeletal muscle and liver of control 
and IRΔper mice was assessed. Consistent with abrogated insulin action as a consequence 
of insulin receptor deficiency, insulin failed to activate phosphorylation of proteinkinase 
B (Akt) in skeletal muscle of IRΔper mice following in vivo insulin stimulation (Fig. 10). 
Similarly, insulin-stimulated Akt phosphorylation was reduced by ~ 80% in liver of 
IRΔper mice (Fig. 10). 
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Fig. 10: Abrogated insulin signaling in peripheral organs of IRΔper mice.  
(A) Western blot analysis of IR, phosphorylated AKT (pAKT) and AKT (loading control) in skeletal 
muscle and liver of ControlΔper and IRΔper mice after injection of either saline (-) or insulin (+) into the 
Vena cava inferior. (B) Relative phosphorylation of AKT in skeletal muscle and liver of ControlΔper and 
IRΔper mice as assessed in (A). pAKT protein amount was normalized to AKT protein expression. pAKT 
expression of saline injected mice was set to 100%. Values are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01 
versus control. Black bars = saline; white bars = insulin. 
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3.2 Inducible inactivation of the insulin receptor in 
peripheral tissues and the central nervous system of adult 
mice 
 To investigate the relative contribution of insulin resistance in the CNS in an 
inducible fashion in addition to peripheral insulin resistance, a second mouse model was 
employed in which transcription of a small hairpin RNA (shRNA) is directed against 
the insulin receptor. This shRNA is under transcriptional control of the human H1/U6 
promoter, which contains a tetracycline-operated sequence (tetO). In the presence of the 
tet repressor (tetR), transcription of the shRNA is silenced. Upon doxycycline 
administration, the tet repressor is sequestered from the promoter, thus allowing for 
ubiquitous transcription of the insulin receptor shRNA (Fig. 11) (120, 195).  
 
 
Fig. 11: General scheme of the inducible whole body insulin receptor knockout mouse (IRΔwb). 
Expression of an insulin receptor-specific short hairpin RNA (shRNA) is dependent on the RNA-
Polymerase III (Pol III)-dependent promoters H1/U6, containing the operator sequences (tetO) of the E. 
coli tetracycline resistance operon. Binding of the tetracycline resistance operon repressor (tetR) to tetO 
prevents transcription. Doxycycline (Dox) sequesters tetR and enables the binding of Pol III to the H1/U6 
promoter, which results in transcription of the shRNA. The shRNA is processed to a siRNA, which binds 
to its complementary mRNA sequence, leading to the degradation of the insulin receptor mRNA. 
 
 Adult mice carrying this transgene (IRΔwb) and wildtype littermates (ControlΔwb) 
were given doxycycline-supplemented water for 30 days and expression of the insulin 
receptor was analyzed in various tissues. Upon doxycycline-mediated induction of 
shRNA transcription, there was a similar decrease in insulin receptor expression in 
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skeletal muscle and liver compared to IRΔper mice, but additionally there was a 
significant reduction of insulin receptor expression in the CNS (Fig. 12).  
 
 
 
Fig. 12: Insulin receptor deficiency in central and peripheral organs of IRΔwb mice.  
(A) Western blot analysis of IR and AKT (loading control) in whole brain, skeletal muscle, liver and 
white adipose tissue (WAT) of ControlΔwb, IRΔwb, ControlΔper and IRΔper mice. Indicated tissues were 
dissected 30 days after the start of inducer administration, except WAT of ControlΔwb and IRΔwb mice, 
which was extracted 7 days after start of doxycycline administration. (B) Relative insulin receptor 
expression of ControlΔper (black bars), IRΔper mice (white bars), ControlΔwb (grey bars) and IRΔwb mice 
(striped bars) as assessed in (A). Values are mean ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 versus 
control. 
 
 In conclusion, the two inducible insulin resistance mouse models here described 
display a similar degree of insulin receptor inactivation in peripheral tissues, while the 
doxycycline-regulated shRNA expression in IRΔwb mice also results in the significant 
reduction of insulin receptor expression in the CNS. Thus, a comparative analysis of 
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these two mouse strains allows insights into the additional effect of neuronal insulin 
resistance in comparison to peripheral insulin resistance. 
 
3.3 Combined central and peripheral insulin resistance leads 
to a more severe lipodystrophy than peripheral insulin 
resistance 
 Analysis of body weight upon insulin receptor inactivation in IRΔper and IRΔwb 
mice revealed that acute inactivation of the insulin receptor in peripheral tissues of adult 
mice has only a modest effect on the regulation of body weight. Only a transient 
decrease in body weight was observed between day 6 and 18 after tamoxifen treatment 
of IRΔper mice (Fig. 13). In contrast, IRΔwb mice exhibited a continuous decrease in body 
weight upon induction of the insulin receptor shRNA (Fig. 13).  
 
 
Fig. 13 Changes in body weight in insulin receptor deficient mice.  
Body weight as percentage of initial body weight of ControlΔper (black bars, n = 24-44), IRΔper (white bars, 
n = 12-42), ControlΔwb (grey bars, n = 4-28) and IRΔwb mice (striped bars, n = 6-17) mice, over 30 days 
after start of either tamoxifen or doxycycline administration. Values are mean ± SEM. *P ≤ 0.05; ***P ≤ 
0.001 versus respective controls. 
 
 Although both mouse models displayed the same degree of insulin receptor 
deficiency in white adipose tissue as determined by Western blot analysis (Fig. 12), 
almost no residual white adipose tissue was detectable in IRΔwb mice 30 days after start 
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of treatment, while IRΔper mice exhibited a reduction in white adipose tissue mass of 
40% (Fig. 14).  
 
 
Fig. 14: Reduction of white adipose tissue mass in insulin receptor deficient mice.  
Average weight of epigonadal fat pads of ControlΔper (black bars, n = 19), IRΔper (white bars, n = 18), 
ControlΔwb (grey bars, n = 18) and IRΔwb mice (striped bars, n = 13) mice, 30 days start of inducer 
administration. Values are mean ± SEM. *P ≤ 0.05 versus ControlΔper; ***P ≤ 0.001 versus ControlΔwb. 
 
 In accordance, assessment of body composition using nuclear magnetic 
resonance revealed a highly significant reduction in whole body fat mass of IRΔwb mice, 
while the differences in fat mass detected between tamoxifen-treated IRΔper mice and 
littermate controls did not reach significance (Fig. 15). 
 
 
Fig. 15: Body composition in insulin receptor deficient mice.  
Total lean mass (white bars) and total fat mass (black bars) of ControlΔper (n = 9), IRΔper mice (n = 5), 
ControlΔwb (n = 8) and IRΔwb mice (n = 12) measured by nuclear magnetic resonance. Values are mean ± 
SEM. ***P ≤ 0.001 versus ControlΔwb. 
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 To establish whether the reduction in adipose tissue represented a tissue-specific 
phenomenon or was also detectable in other organs of IRΔwb mice, organ weight of liver, 
skeletal muscle, brain, kidney, lung and heart of IRΔwb mice was determined. This 
analysis revealed a selectively reduced mass of white adipose tissue, while weights of 
the other organs tested remained unchanged in IRΔwb mice compared to controls (Fig. 
16). 
In summary, these experiments reveal that combined insulin resistance in the 
CNS and peripheral organs leads to a much more pronounced lipodystrophic phenotype 
than insulin resistance restricted to the periphery, including white adipose tissue. 
 
 
Fig. 16: Adipose tissue-specific hypoplasia in IRΔwb mice.  
Tissue weight of liver, muscle, brain, white adipose tissue (WAT), kidney, lung and heart, correlated to 
body weight, of ControlΔwb (n = 8-13) and IRΔwb mice (n = 8-16) 30 days after start of doxycycline 
administration. Values are mean ± SEM. ***P ≤ 0.001 versus ControlΔwb. 
 
3.4 Intracerebroventricular infusion of insulin leads to 
increased lipogenesis 
 It is well documented that insulin inhibits lipolysis in adipocytes via activation 
of the insulin receptor expressed on these cells (196-198). In light of the more 
pronounced lipodystrophy detected in IRΔwb mice, it was addressed whether insulin 
acting via the CNS has additional effects on adipocyte function. To this end, C57BL/6 
mice received a chronic intracerebroventricular infusion of either insulin or carrier 
solution over a period of 7 days. Peripheral insulin levels were determined on the first 
and last day of insulin infusion and were found to be unchanged between insulin and 
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carrier infused mice, thereby ruling out the possibility of insulin leaking from the brain 
into the periphery and directly acting on peripheral tissues (Fig. 17). 
 
 
Fig. 17: Chronic icv infusion of insulin has no effect on peripheral insulin concentrations in 
C57BL/6 mice.  
Serum insulin concentrations of C57BL/6 mice receiving chronic intracerebroventricular infusion of 
carrier (black bars, n = 5) or insulin solution (white bars, n = 5) at a rate of 200 µU per day over 7 days. 
Day 0 = day of icv cannula and insulin osmotic mini-pump implant. Values are mean ± SEM. 
 
While insulin administration into the right lateral ventricle did not affect food 
intake or overall body weight, white adipose tissue mass of mice receiving 
intracerebroventricular insulin infusions was slightly but significantly elevated (Fig. 
18). 
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Fig. 18: Chronic icv infusion of insulin increases adipose tissue mass without changes in body 
weight or food intake in C57BL/6 mice.  
(A) Mean body weight, (B) average daily food intake and (C) epigonadal fat pad weight corrected for 
body weight of C57BL/6 mice receiving chronic intracerebroventricular infusion of carrier (black bars, n 
= 5) or insulin solution (white bars, n = 5) at a rate of 200 µU per day over 7 days. Day 0 = day of icv 
cannula and insulin osmotic mini-pump implant. Values are mean ± SEM. *P ≤ 0.05 versus control. 
 
 The increase in adipose tissue mass was also reflected in an augmented 
adipocyte size as determined by histological and computational analysis (Fig. 19). In 
addition, mRNA analysis revealed an increase of the lipogenesis-promoting enzyme 
lipoprotein lipase in white adipose tissue (Fig. 19). These data directly indicate that 
insulin action in the CNS, in addition to its fat-cell-autonomous inhibition of lipolysis, 
promotes lipogenesis. 
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Fig. 19: Chronic icv infusion of insulin increases lipogenesis in C57BL/6 mice.  
(A) H&E staining of white adipose tissue (magnification: 100x), (B) mean adipocyte size and (C) relative 
mRNA expression of lipoprotein lipase (LPL) in white adipose tissue of C57BL/6 mice after 7 days of 
chronic intracerebroventricular infusion of carrier (black bars, n = 5) or insulin (white bars, n = 5) at a 
rate of 200 µU per day. Values are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01 versus control. 
 
3.5 Insulin inhibits adipocyte-autonomous leptin secretion 
 Given the differential regulation of white adipose tissue mass, the concentrations 
of different adipokines were measured at several time points after induction of insulin 
receptor deficiency in IRΔper mice and IRΔwb mice. Analysis of circulating serum leptin 
concentrations revealed a constant increase in plasma leptin levels in IRΔper mice 
compared to control animals after induction of insulin receptor deletion in peripheral 
tissues (Fig. 20).  
 
Fig. 20: Peripheral insulin resistance results in an increase in total serum leptin concentrations. 
Total serum leptin levels of ControlΔper (n = 18) and IRΔper mice (n = 18) over a period of 30 days.  Mice 
were administered tamoxifen from day 1 until day 5. Values are mean ± SEM. **P ≤ 0.01, ***P ≤ 0.001 
versus ControlΔper. 
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 In contrast, deleting the insulin receptor additionally in the CNS of IRΔwb mice 
led to a progressive decline in circulating serum leptin concentrations (Fig. 21).  
 
 
Fig. 21: Whole body insulin resistance results in a decrease in total serum leptin concentrations. 
Total serum leptin levels of ControlΔwb (n = 5) and IRΔwb mice (n = 5) over the course of 30 days. Mice 
were administered doxycycline from day 1 onwards. Values are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001 versus ControlΔwb. 
 
 However, when leptin concentrations were corrected for epigonadal fat pad 
weight, both IRΔper and IRΔwb mice exhibited a staggering increase in leptin levels 
compared to their tamoxifen- or doxycycline-treated littermate controls (Fig. 22). In the 
same manner, serum adiponectin levels were found to be significantly increased in 
IRΔper and IRΔwb mice when correlated with white adipose tissue mass (Fig. 22). 
 
 
Fig. 22: Serum adipokine levels correlated with white adipose tissue mass in insulin receptor 
deficient mice. 
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(A) Serum leptin levels correlated to epigonadal fat pads of ControlΔper (black bars; n = 17), IRΔper (white 
bars; n = 13), ControlΔwb (grey bars; n = 13) and IRΔwb mice (striped bars; n = 6). (B) Serum adiponectin 
levels correlated to epigonadal fat pad weight of ControlΔper (black bars; n = 13), IRΔwb (white bars; n = 
10), ControlΔwb (grey bars; n = 13) and IRΔwb mice (striped bars; n = 16). Serum samples were measured 
30 days after start of tamoxifen or doxycycline administration. Values are mean ± SEM. *P ≤ 0.05,  ***P 
≤ 0.001 versus respective controls. 
 
 In conclusion, lack of insulin receptor expression in adipocytes results in an 
increase in leptin secretion from the adipose tissue. In the case of the IRΔwb mice, this 
effect is masked by the more predominant phenotype of reduced adipose tissue mass, 
whereas the rise in serum leptin levels remains detectable in the IRΔper mice, due to the 
smaller reduction of absolute fat mass in these mice. 
 
3.6 Peripheral and central insulin action regulate hepatic 
ObRb expression 
Next, the potential impact of increased leptin concentrations on leptin signal 
transduction in peripheral tissues was analyzed, by determining the expression of the 
long form of the leptin receptor (ObRb) in liver of IRΔper and IRΔwb mice. This analysis 
revealed a 76-fold increase in ObRb mRNA expression in IRΔper compared to control 
mice (Fig. 7a). In IRΔwb mice, a significant increase in hepatic ObRb mRNA expression 
could also be detected, although to a lesser extent than in IRΔper mice (Fig. 23).  
 
 
Fig. 23: Peripheral and central insulin receptor deficiency increases hepatic ObRb mRNA 
expression.  
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(A) Relative mRNA expression of hepatic ObRb of ControlΔper (black bars; n = 8) and IRΔper (white bars; 
n = 7) mice 30 days after start of tamoxifen administration. Values are mean ± SEM. ***P ≤ 0.001 versus 
control. (B) Relative mRNA expression of hepatic ObRb of ControlΔwb (black bars; n = 5) and IRΔwb 
(striped bars; n = 4) mice 30 days after start of doxycycline administration. Values are mean ± SEM. **P 
≤ 0.01 versus control. 
 
 In both mouse models, the rise in ObRb mRNA was reflected by a rise in ObRb 
protein expression as shown by Western blot analysis, while almost no immunoreactive 
ObRb was present in the liver of tamoxifen- or doxycycline-treated control mice (Fig. 
24). 
 
 
Fig. 24: Peripheral and central insulin receptor deficiency increases hepatic ObRb protein 
expression.  
Western blot analysis of ObRb and AKT (loading control) in liver of ControlΔwb, IRΔwb, ControlΔper and 
IRΔper mice. Tissues were excised 30 days after the start of inducer administration. ObRb expression is 
also visualized as a comparative densitometric analysis with the average of ObRb expression of 
respective controls set to 100%. Values are mean ± SEM. *P ≤ 0.05 versus control. 
 
 To determine whether the increment in hepatic ObRb expression in the presence 
of elevated leptin concentrations resulted in an increased leptin receptor signaling, the 
expression and tyrosine phosphorylation of the downstream target of leptin signaling 
signal transducer and activator of transcription (Stat)-3 was determined. While hepatic 
Stat-3 protein expression remained indistinguishable between control and IRΔper mice, a 
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significant increase in tyrosine phosphorylated Stat-3 could be detected in IRΔper mice 
(Fig. 25). In contrast, both expression and tyrosine phosphorylation of Stat-3 were 
unaltered in IRΔwb mice compared to control mice (Fig. 25), indicating that both acute 
selective peripheral and whole body insulin resistance lead to ObRb upregulation in 
liver, but central insulin action is needed for hepatic Stat-3 activation. 
 
 
Fig. 25: Peripheral but not central insulin receptor deficiency results in an increase in hepatic Stat-
3 phosphorylation.  
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(A) Western blot analysis of Stat-3, phosphorylated Stat-3 (pStat-3) and AKT (loading control) in liver of 
ControlΔper and IRΔper mice. The tissue was excised 30 days after the start of the tamoxifen administration. 
(B) Western blot analysis of Stat-3, pStat-3 and AKT (loading control) in liver of ControlΔwb and IRΔwb 
mice. The tissue was excised 30 days after the start of doxycycline administration. (C) Stat-3 
phosphorylation of ControlΔper (black bars) and IRΔper mice (white bars) was quantified via comparative 
densitometric analysis with the average of phosphorylated Stat-3 in ControlΔper mice set to 100%. Values 
are mean ± SEM. *P ≤ 0.05 versus control. (D) Stat-3 phosphorylation of ControlΔwb (grey bars) and 
IRΔwb mice (striped bars) was quantified via comparative densitometric analysis with the average of 
phosphorylated Stat-3 in ControlΔwb mice set to 100%. Values are mean ± SEM.  
 
3.7 Central insulin action regulates hepatic IL-6 mRNA levels 
 Recently, insulin was demonstrated to activate hypothalamic insulin signaling 
leading to increased hepatic interleukin (IL)-6 mRNA expression resulting in Stat-3 
phosphorylation in hepatocytes (199), a process specifically regulated via AgRP 
neurons (200). As insulin receptor expression in the brain is unaltered in IRΔper mice and 
since these mice exhibit increased circulating serum insulin concentrations, intact 
neuronal insulin signal transduction may lead to upregulation of hepatic IL-6 mRNA 
expression. Indeed, we observed a significant 2.5-fold upregulation of IL-6 mRNA 
expression in the liver of IRΔper mice (Fig. 26).  
 
 
Fig. 26: Peripheral insulin receptor deficiency results in an increase in hepatic IL-6 mRNA 
expression.  
Relative mRNA expression of IL-6 in liver of ControlΔper (black bars; n = 8) and IRΔper (white bars; n = 7) 
mice. Data was collected 25 days after the last tamoxifen administration. Values are mean ± SEM. **P ≤ 
0.01 versus control. 
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Thus, the observed increased Stat-3 phosphorylation in the liver of IRΔper mice 
may result either from signal transduction via the hepatic ObRb or via the hepatic IL-6 
receptor, possibly as a consequence of increased hepatic IL-6 expression due to intact 
neuronal insulin signaling in the presence of elevated serum insulin concentrations. In 
contrast to IRΔper mice, hepatic IL-6 mRNA expression remained unaltered in IRΔwb 
mice (Fig. 27), indicating a role for central insulin in the regulation of hepatic IL-6 
mRNA expression. 
 
 
Fig. 27: Unaltered IL-6 mRNA expression in the liver of IRΔwb mice.  
Relative mRNA expression of interleukin 6 (IL-6) in liver of ControlΔwb (black bars; n = 7) and IRΔwb 
(white bars; n = 7) mice. Data was collected 30 days after the start of doxycycline administration. Values 
are mean ± SEM. P = 0.06 versus ControlΔwb. 
 
3.8 IRΔwb mice display a higher degree of impaired peripheral 
glucose metabolism 
To determine the regulation of peripheral glucose metabolism after acute 
induction of peripheral or whole body wide insulin resistance, blood glucose levels in 
randomly fed mice were assessed daily from the period of induction with either 
tamoxifen in IRΔper or doxycycline in IRΔwb mice. An early onset rise of blood glucose 
concentrations in IRΔwb mice reaching 600 mg/dl 17 days after the beginning of 
doxycycline induction was observed (Fig. 28). IRΔper mice also exhibited a clear 
increase in blood glucose concentrations after completion of tamoxifen treatment. 
Nevertheless, both the kinetics of hyperglycemia onset and the magnitude of 
hyperglycemia reached were significantly lower in IRΔper mice (Fig. 28). Blood glucose 
concentration reached the maximum of approximately 400 mg/dl 17 days after start of 
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tamoxifen administration and stayed stable in this range during the following 2 weeks 
(Fig. 28). 
 
 
Fig. 28: Loss of central insulin receptor signaling results in more pronounced hyperglycemia.  
Random fed blood glucose concentrations of ControlΔper (filled squares; n = 3-50), IRΔper (open squares; n 
= 3-48), ControlΔwb (grey triangles; n = 5-27) and IRΔwb mice (open triangles; n = 5-32) over 30 days. 
Data represent the mean ± SEM. **P ≤ 0.01, ***P ≤ 0.001 versus respective controls. 
 
 Accordingly, glucose tolerance tests performed at day 18 after induction of IR 
ablation in both mouse models disclosed a significant impairment of glucose tolerance 
in IRΔper mice (Fig. 29). Fasting blood glucose concentrations remained unaltered at the 
same time point (Fig. 29). 
 
 
Fig. 29: Impaired glucose tolerance in IRΔper mice.  
Glucose tolerance tests in ControlΔper (filled squares, n = 18) and IRΔper (open squares; n = 19) mice. 
Blood glucose concentrations were measured immediately before and 15, 30, 60 and 120 minutes after 
injection of 2 g/kg of glucose. Data represent the mean ± SEM. *P ≤ 0.05, **P ≤ 0.01 versus control. 
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 IRΔwb mice, on the other hand, exhibited a significant increase in fasting blood 
glucose concentrations, but also reacted with a significantly higher rise in blood glucose 
concentrations upon exogenous glucose administration (Fig. 30). Since IR deletion 
occurred to a similar extent in peripheral tissues of IRΔper and IRΔwb mice, this data 
indicates that lack of the insulin receptor in the CNS of IRΔwb mice leads to a 
significantly more severe impairment of peripheral glucose homeostasis. 
 
 
Fig. 30: Impaired glucose tolerance in IRΔwb mice. 
 Glucose tolerance tests in ControlΔwb (grey triangles; n = 9) and IRΔwb (open triangles; n = 13) mice. 
Blood glucose concentrations were measured immediately before and 15, 30, 60 and 120 minutes after 
injection of 2 g/kg of glucose. Data represent the mean ± SEM. **P ≤ 0.01, ***P ≤ 0.001 versus control. 
 
3.9 Leptin administration improves glucose metabolism in 
IRΔwb mice 
 To analyze whether loss of signaling via hepatic Stat-3 in IRΔwb mice, either as a 
consequence of reduced hepatic IL-6 expression or due to the absence of leptin, 
contributes to the impairment of peripheral glucose homeostasis, doxycycline-treated 
IRΔwb mice and littermate controls received a chronic leptin infusion over a period of 7 
days via subcutaneously implanted osmotic mini-pumps. Serum leptin levels were 
measured at several time points during chronic administration of leptin. Leptin levels 
were significantly increased as early as two days after pump implant and remained 
elevated to a similar extent in IRΔwb mice and littermate controls over the course of the 
experiment (Fig. 31). 
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Fig. 31: Restoration of serum leptin concentrations of IRΔwb mice.  
Total serum leptin levels of ControlΔwb (grey bars; n = 5) and IRΔwb mice (striped bars; n = 5) receiving a 
chronic infusion of leptin at a rate of 12 µg per day. Blood samples were taken, 2, 4, 6 and 7 days after 
the subcutaneous implantation of an osmotic mini-pump. Mice had been administered doxycycline for 16 
days prior to pump implantation. Values are mean ± SEM.  
 
 Western blot analysis revealed an increase in hepatic Stat-3 tyrosine 
phosphorylation after leptin reconstitution in IRΔwb mice, whereas no phosphorylated 
Stat-3 could be detected in controls receiving leptin infusions (Fig. 32).  
 
 
Fig. 32: Chronic infusion of leptin increases hepatic Stat-3 phosporylation in IRΔwb mice.  
Western blot analysis of pStat-3 and AKT (loading control) in liver of ControlΔwb and IRΔwb mice 
receiving a chronic infusion of leptin at a rate of 12 µg per day. Tissues were excised 7 days after the 
subcutaneous implantation of the osmotic mini-pump. 
 
 Strikingly, in parallel to increased hepatic Stat-3 phosphorylation in IRΔwb mice 
receiving leptin infusion, blood glucose levels decreased dramatically two days after 
start of leptin infusion to levels comparable to those found in control mice (Fig. 33).  
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Fig. 33: Restoration of hepatic Stat-3 phosporylation ameliorates blood glucose concentrations.  
Random fed blood glucose concentrations of ControlΔwb (grey triangles; n = 5) and IRΔwb mice (open 
triangles; n = 5) receiving a chronic infusion of leptin at a rate of 12 µg per day from day 16 onwards. 
Data represent the mean ± SEM. *P ≤ 0.05, ***P ≤ 0.001 versus control. 
 
 Taken together, the data show that increasing hepatic Stat-3 activation largely 
ameliorates dysregulated glucose metabolism in IRΔwb mice. 
 
3.10 Peripheral insulin resistance results in β cell hyperplasia 
but unaltered insulin secretion 
 As insulin resistance restricted to pancreatic β cells throughout development has 
been demonstrated to impair insulin secretion, serum insulin concentrations and the 
insulin secretory response to exogenously applied glucose in IRΔper and IRΔwb mice were 
determined. Assessment of serum insulin concentrations revealed that both IRΔper and 
IRΔwb mice suffer from severe hyperinsulinemia as an indirect measure of peripheral 
insulin resistance upon induction of insulin receptor ablation. IRΔper mice reached a 
maximum 50-fold increase on day 18, while IRΔwb mice displayed their maximum on 
day 12 following the induction of IR ablation, exhibiting a 54-fold increase of 
circulating plasma insulin concentrations (Fig. 34). 
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Fig. 34: Peripheral and whole body insulin receptor deficiency results in hyperinsulinemia.  
Plasma insulin concentrations in ControlΔper (black bars; n = 14 – 24), IRΔper (white bars; n = 13 - 23), 
ControlΔwb (grey bars; n = 5) and IRΔwb (striped bars; n = 4 - 5) mice over 30 days. Data represent the 
mean ± SEM. ***P ≤ 0.001 versus respective controls. 
 
 Further analysis revealed a significant increase in fasting serum insulin 
concentrations in IRΔper and even higher levels in IRΔwb mice, consistent with the degree 
of insulin resistance in these mouse models (Fig. 35). Following an intravenous 
injection of glucose, serum insulin concentrations of IRΔper mice were significantly 
elevated, both acutely within 2 to 5 minutes after glucose injections and in a prolonged 
fashion 30 minutes after injection (Fig. 35), whereas the typical diphasic pattern of 
glucose-stimulated insulin secretion was disrupted in IRΔwb mice. 
 
 
Fig. 35: Glucose-stimulated insulin secretion in IRΔper and IRΔwb mice.  
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Insulin concentrations after administration of an exogenous glucose bolus in ControlΔper (filled squares; n 
= 8), IRΔper (open squares; n = 5), ControlΔwb (grey triangles; n = 5) and IRΔwb mice (open triangles; n = 8) 
on day 18. Values are mean ± SEM. ***P ≤ 0.001 versus control. 
 
 Histological analysis of pancreatic tissues revealed a clear β cell hyperplasia 
upon induced insulin receptor ablation in both mouse models, consistent with the β cell 
proliferative response to insulin resistance (Fig. 36). Despite a significant enlargement 
of pancreatic islets both in IRΔper and IRΔwb mice, their architecture appeared normal 
with unaltered distribution of insulin producing β cells and glucagon producing α cells 
(Fig. 36).  
 
 
Fig. 36: Peripheral and central insulin resistance results in β cell hyperplasia.  
Immunohistochemical stainings of pancreatic islets in ControlΔper, IRΔper, ControlΔwb and IRΔwb mice. 
Pancreatic tissues were stained for H&E, Insulin and Glucagon. Magnification: x100. 
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 Quantitative assessment of β cell mass exhibited a significant increase in β cell 
mass 3 weeks after induction of insulin receptor deficiency indicating a fast 
hyperproliferative β cell response to peripheral insulin resistance (Fig. 37). 
 
 
Fig. 37: Increased β cell mass in IRΔper and IRΔwb mice.  
Percentage of β cell mass in ControlΔper (black bars; n = 4) and IRΔper mice (white bars; n = 4), ControlΔwb 
(grey bars; n = 3) and IRΔwb mice (striped bars; n = 3). Data was collected 30 days after starting the 
experiment. Values are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01  versus control. 
 
 These data indicate that in response to acutely induced insulin resistance in adult 
mice, even within pancreatic β cells themselves, β cell mass remains dynamic and still 
allows for the occurrence of β cell hyperplasia. If insulin resistance remains peripheral, 
the hyperproliferative β cells are still capable of secreting insulin acutely in response to 
exogenously administered glucose. 
 
3.11 Targeted disruption of the IGF-1 receptor allele 
Since there is strong evidence for a redundancy of insulin and IGF-1 signal 
transduction, and both signaling pathways contribute to the regulation of neuronal 
growth and survival, as well as the regulation of food intake and peripheral glucose 
metabolism, the IGF-1 receptor gene was specifically inactivated in the central nervous 
system of mice, by using a targeting construct to introduce two loxP-sites into the 
murine IGF-1 receptor gene (Fig. 38). Cre-mediated recombination and subsequent 
excision of exon 3 of the IGF-1 receptor gene results in a frame shift after 213 codons, 
with an appended sequence of 27 amino acids followed by a stop codon in exon 4. 
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Fig. 38: Conditional gene targeting strategy.  
Location of the probe used for Southern blot analysis is indicated by a black bar. BamHI = restriction 
enzyme sites, 2, 3, 4 = exon 2, 3 or 4 of the Igf-1 receptor gene, neor = neomycin resistance gene cassette, 
HSV-tk = Herpes simplex virus thymidine kinase gene cassette. 
 
After transfection of Bruce4 ES cells with this construct, ES cell clones were 
identified in which the construct had been integrated in the endogenous IGF-1 receptor 
gene locus by homologous recombination. By combined Southern blot and PCR 
analysis, the integrity of the IGF-1 receptor gene surrounding the construct integration 
site was confirmed both at the 3’ and 5’-end (Fig. 39).  
 
 
 
Fig. 39: Correct construct integration into the endogenous IGF-1 receptor locus.  
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Southern blot analysis using the 5’-probe and PCR analysis using primers flanking the 3’-loxP site of 
homologous ES cell clones isolated after transfection with the linearized targeting vector. 
 
 Taken together, successful integration of the loxP-sites surrounding exon 3 of the 
IGF-1 receptor gene was established. Deletion of exon 3 has been demonstrated to yield 
a functionally inactive IGF-1 receptor gene, lacking the extracellular ligand binding 
domain, the transmembrane region, as well as the intracellular tyrosine kinase domain 
(201). Injection of the homologous recombinant ES cell clone into blastocysts yielded 
chimeric mice, which consist of two cell types of different origin, as becomes visible 
when using donor mice of different coat colors for the ES cells and the blastocyst. 
Chimeric mice carrying the mutated IGF-1 receptor allele ranged between 30% and 
90% chimerism according to coat color (Fig. 40).  
 
 
Fig. 40: Chimeras heterozygous for the mutated IGF-1 receptor allele.   
Picture of IGF1Rflox/+ chimeras generated by injection of a homologous recombinant Bruce4 ES cell clone 
into a CB-20 blastocyst. 
 
 Backcrossing the chimeric mice with C57BL/6 mice resulted in germline 
transmission of the mutation, as could be assessed by PCR analysis (Fig. 41). 
 
 
Fig. 41: Germline transmission of the mutated IGF-1 receptor allele.  
PCR of the 3’ loxP site performed on DNA of tail biopsies from mice born of an IGF1Rflox/+-chimera/Flp 
deleter breeding. 
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Since the construct carries a neomycin resistance gene, which might interfere with 
the transcription and translation of the modified IGF-1 receptor allele, the resistance 
cassette was initially flanked by FRT recombination sites, allowing for excision by Flp 
recombinase-mediated recombination. To this end, backcrossing was performed into 
mice expressing the Flp recombinase in their germline (FlpE deleter). Since the FlpE 
deleter mice had previously been backcrossed onto a C57BL/6 background for eight 
generations, offspring from the chimeras carrying the IGF-1 receptor mutation on a pure 
C57BL/6 background and the FlpE deleter mice yielded double-transgenic animals 
without a neomycin resistance gene and a genetic background contributed by more than 
99.9% from the C57BL/6 strain. These mice were bred to mice expressing the Cre 
recombinase under the control of the neuron-specific rat Synapsin 1 promoter (187, 
202) to yield mice heterozygous for an IGF-1 receptor deficiency exclusively in neural 
tissues (hetIGF1RΔSyn). hetIGF1RΔSyn, in turn, were intercrossed to obtain mice 
homozygous for the loxP-flanked IGF-1 receptor allele either with Cre expression 
(IGF1RΔSyn) or without Cre expression (ControlΔSyn) to be used as littermate controls. 
 
3.12 Conditional inactivation of the IGF-1 receptor gene in 
the central nervous system 
The efficiency of IGF-1 receptor gene recombination was assessed by Western blot 
analysis and immunohistochemistry. To this end, brain tissue was removed from 
IGF1RΔSyn mice and littermate controls and expression of the IGF-1 receptor protein 
was determined for a number of different brain regions. IGF-1 receptor protein 
expression was found to be significantly reduced by 90% in the hippocampus of 
IGF1RΔSyn mice, whereas expression levels were indistinguishable from that of control 
littermates for the region of the cerebellum. A reduction in IGF-1R protein expression 
of approximately 70% could also be detected in the parietal cortex of IGF1RΔSyn mice. 
However, these values did not reach significance. 
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Fig. 42: Central IGF-1 receptor protein expression.  
Western blot and densitometric analysis of IGF-1R and actin (loading control) expression in protein 
lysates from different brain regions such as hippocampus, parietal cortex and cerebellum of 12-week-old 
IGF1RΔSyn mice (white bars, n = 3) and littermate controls (black bars, n = 3). Values represent the mean 
± SEM. **P ≤ 0.01 versus controls. 
 
On the other hand, IGF-1 receptor protein expression in the periphery was found to 
be unchanged from that of littermate controls in tissues such as heart, skeletal muscle, 
pancreas and lung (Fig. 43). 
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Fig. 43: Peripheral IGF-1 receptor protein expression.  
Western blot and densitometric analysis of IGF-1R and actin (loading control) expression in protein 
lysates from heart, skeletal muscle, pancreas and lung of 28-week-old IGF1RΔSyn mice (white bars, n = 3) 
and littermate controls (black bars, n = 3). Data represent the mean ± SEM. 
 
Cre-mediated recombination was also visualized using a reporter mouse strain in 
which transcription of the β-galactosidase gene (LacZ) under the control of the 
ubiquitously expressed Rosa26 promoter is prevented by a loxP-flanked hygromycin 
resistance gene (RosaArte1) (100). Expression of the Cre recombinase under the control 
of the Synapsin-1 promoter enables transcription of LacZ in Synapsin-1-expressing 
neurons, which can be visualized by immunofluorescent staining of brains of Synapsin 
Cre-expressing LacZ (SynCre-LacZ) mice. Cre expression under the control of the 
Synapsin-1 promoter was confirmed in the dentate gyrus (Fig. 44), a region of the 
hippocampus which has been implicated in neurogenesis (203-205), a process linked to 
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learning and memory, and to a lesser extent in the cortex of SynCre-LacZ mice, thereby 
paralleling the previous results found by Western blot analysis. 
 
 
Fig. 44: Synapsin Cre expression in brain regions of SynCre-LacZ mice.  
Fluorescence immunohistochemical stainings of the dentate gyrus and the cortex of a SynCre-LacZ 
mouse. Magnification: 200x. Blue = DAPI = DNA, green = FITC = β-Galactosidase = β-Gal. 
 
Histological analysis of brain tissues of IGF1RΔSyn mice and littermate controls 
exhibited a significant reduction in IGF-1 receptor protein expression within the dentate 
gyrus (Fig. 45), co-localizing IGF-1 receptor deletion with those cells expressing the 
Cre recombinase. 
 
Results   
 
-66- 
 
Fig. 45: Reduced IGF-1 receptor expression in the dentate gyrus of IGF1RΔSyn mice.  
Fluorescence immunohistochemical stainings of brains of ControlΔSyn and IGF1RΔSyn mice. Magnification: 
200x. Blue = DAPI = DNA, red = Rhodamin = β-Galactosidase (β-Gal), green = FITC = IGF-1R. 
 
In conclusion, these experiments demonstrate the generation of a central IGF-1 
receptor deficiency in IGF-1RΔSyn mice without significant recombination occurring in 
the periphery. 
 
3.13 Physiological characterization of IGF-1RΔSyn mice 
3.13.1 Energy homeostasis 
To assess the importance of central IGF-1 receptor action in the regulation of 
energy homeostasis, body weight of IGF-1RΔSyn and IGF-1Rflox/flox (ControlΔSyn) mice 
was monitored from weaning, 3 weeks after birth, until 7 months of age. This analysis 
revealed a reduction in body weight of IGF-1RΔSyn mice compared to littermate controls 
on the day of weaning, which became indistinguishable from the age of 4 weeks on and 
remained thus (Fig. 46). 
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Fig. 46: Body weight of IGF-1RΔSyn mice.  
Average body weight of ControlΔSyn (black squares, n = 24) and IGF-1RΔSyn mice (white squares, n = 17), 
over 30 weeks. Litters were weaned at week 3. Values are mean ± SEM. *P ≤ 0.05 versus control. 
 
Consistent with these findings, nuclear magnetic resonance analysis revealed no 
differences between fat or lean mass of adult IGF-1RΔSyn and littermate controls (Fig. 
47). 
 
 
Fig. 47: Unaltered body composition of IGF-1RΔSyn mice. 
Fat mass (black bars) and lean mass (white bars) of ControlΔSyn (n = 6) and IGF-1RΔSyn mice (n = 3) at the 
age of 12 weeks. Values are mean ± SEM. 
  
Accordingly, epigonadal fat pad weights were unaltered and no changes were 
detected in circulating serum leptin and insulin concentrations in adult IGF-1RΔSyn mice 
when compared to controls (Fig. 48).  
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Fig. 48: Central IGF-1 receptor deficiency has no impact on adipose tissue mass or serum leptin 
and insulin concentrations.  
(A) Average weight of epigonadal fat pad correlated to body weight of ControlΔSyn (black bars, n = 3) and 
IGF-1RΔSyn mice (white bars, n = 5) at the age of 30 weeks. Values are mean ± SEM. (B) Total serum 
leptin levels of ControlΔSyn (black bars, n = 12) and IGF-1RΔSyn mice (white bars, n = 20).  Values are 
mean ± SEM. (C) Total serum insulin levels of ControlΔSyn (black bars, n = 6) and IGF-1RΔSyn mice 
(white bars, n = 11). Values are mean ± SEM.  
 
Taken together, these experiments indicate that energy homeostasis in adult 
mice is unaffected by the targeted disruption of the IGF-1 receptor gene in the central 
nervous system, at least in those neurons targeted by the Synapsin-1-Cre transgene. 
 
3.13.2 Glucose homeostasis 
To analyze the contribution of neuronal IGF-1 receptor signaling in Synapsin-1 
positive neurons in the regulation of peripheral glucose homeostasis, glucose 
concentrations were determined in 18-week-old IGF-1RΔSyn mice. This analysis 
revealed that glucose concentrations were indistinguishable between IGF-1RΔSyn mice 
and littermate controls both in a random fed and in a fasted state (Fig. 49).  
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Fig. 49: Loss of central IGF-1 receptor signaling has no impact on blood glucose concentrations.  
(A) Random fed blood glucose concentrations of 18-week old ControlΔSyn (filled bars; n = 9) and IGF-
1RΔSyn mice (white bars; n = 5). Data represent the mean ± SEM. (B) Fasted blood glucose concentrations 
of 18-week old ControlΔSyn (filled bars; n = 9) and IGF-1RΔSyn mice (white bars; n = 5). Data represent the 
mean ± SEM. 
 
 In addition, no significant changes could be detected when assessing glucose 
tolerance through i.p. administration of an exogenous glucose challenge. Both IGF-
1RΔSyn mice and littermate controls reacted with a similar increase in blood glucose 
concentrations and although glucose clearance from the blood appeared at first delayed 
in IGF-1RΔSyn mice, all animals returned to original concentrations after 120 minutes 
(Fig. 53). 
 
 
 
Fig. 50: Unaltered glucose tolerance in IGF-1RΔSyn mice.  
Glucose tolerance test in 18-week-old ControlΔSyn (filled squares, n = 9) and IGF-1RΔSyn mice (open 
diamonds; n = 5). Blood glucose concentrations were measured immediately before and 15, 30, 60 and 
120 minutes after injection of 2 g/kg of glucose. Data represent the mean ± SEM. 
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 To determine insulin sensitivity,  IGF-1RΔSyn mice and littermate controls 
received an i.p. injection of insulin, to which all animals reacted with a 30-35% 
decrease in blood glucose concentrations within 30 minutes after insulin administration, 
before returning to initial levels 60 minutes after injection (Fig. 51). Again, no 
differences were noticeable between IGF-1RΔSyn mice and controls, indicating that loss 
of central IGF-1 signaling does not lead to insulin resistance. 
 
 
Fig. 51: Unaltered insulin sensitivity in IGF-1RΔSyn mice.  
Insulin tolerance test in ControlΔSyn (filled squares, n = 9) and IGF-1RΔSyn mice (open diamonds; n = 5) at 
the age of 18 weeks. Blood glucose concentrations were measured immediately before and 15, 30, and 60 
minutes after injection of 0,75 U/kg of insulin. Data represent the mean ± SEM. 
 
 In conclusion, loss of signaling through the IGF-1 receptor in the CNS 
apparently has no consequence for peripheral glucose homeostasis in the presence of 
normal central insulin action. 
 
3.14 Brain weight is unaffected by central IGF-1R deficiency 
The so-called synRas mice express a constitutively active form of the small 
GTPase Ras in differentiated neurons (206). These animals display severe brain 
hypertrophy due to an increase in cell size, while the number of neurons remains 
unaltered (206). This effect could also be detected specifically in hippocampal neurons 
(207). Since IGF-1 receptor signaling is an important inducer of Ras activity, loss of 
central IGF-1 receptor signaling and thereby Ras activation could potentially lead to the 
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opposite effect, resulting in an atrophy of brain tissues. This holds true for IGF-1-
deficient mice, which exhibit severe reductions in brain size, in particular a reduced 
dentate gyrus granule cell layer, as well as CNS hypomyelination (208). To analyze 
this, brain tissue of IGF-1RΔSyn and control mice was dissected and weighed. No 
significant alterations were detected between IGF-1RΔSyn mice and littermate controls 
(Fig. 52), indicating that loss of central IGF-1 receptor signaling has no visibly 
deleterious effect on the central nervous system. 
 
 
Fig. 52: Unaltered brain weight of IGF-1RΔSyn mice.  
Average brain weight of ControlΔSyn (black bars, n = 8) and IGF-1RΔSyn mice (white bars, n = 8) at the age 
of 19 weeks. Values are mean ± SEM. 
 
3.15 Unaltered susceptibility to kainic acid of IGF-1RΔSyn mice 
Systemic IGF-1 has been shown to increase adult neurogenesis and neuronal 
excitability and is considered a potent neuroprotective factor in the adult brain (189, 
209, 210). The glutamate receptor agonist kainic acid (KA) is a potent excitotoxin that 
causes severe limbic motor seizures culminating in status epilepticus when binding to 
the non-N-methyl-D-aspartate (NMDA) receptors, a subtype of ionotropic glutamate 
receptors (for review see (211)). Administration of KA induces neuronal apoptosis, 
predominantly in the hippocampal subregions cornu ammonis (CA) 1 and CA3, as well 
as the dentate gyrus (DG), and increases production of reactive oxygen species (ROS) 
and mitochondrial dysfunction. 
Upon i.p. administration of KA, IGF-1RΔSyn mice and littermate controls reacted 
with epileptic seizures starting at an average of 40 min and 57 min after injection, 
Results   
 
-72- 
respectively. The maximum seizure score did not differ between IGF-1RΔSyn and control 
mice (Fig. 53). 
 
 
Fig. 53: Central IGF-1 receptor deficiency has no impact on kainic acid-induced seizures.  
(A) Seizure initiation time of ControlΔSyn (black bars, n = 6) and IGF-1RΔSyn mice (white bars, n = 11).  
Values are mean ± SEM. (B) Maximum seizure score of ControlΔSyn (black bars, n = 6) and IGF-1RΔSyn 
mice (white bars, n = 11).  Values are mean ± SEM. 
 
 Assessment of neuronal damage by Nissl staining revealed no significant 
differences in the brain regions targeted predominantly by KA, like the dentate gyrus 
and the CA1 region of the hippocampus (Fig. 54), indicating that loss of central IGF-1 
receptor signaling has no consequence for KA-induced neuronal cell death. 
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Fig. 54: Kainic acid-induced neuronal damage occurs to similar extent in IGF-1RΔSyn and control 
mice.  
(A) Nissl staining of the dentate gyrus region of the hippocampus of ControlΔSyn and IGF-1RΔSyn mice. 
Magnification: 100x. (B) Nissl staining of the CA1 region of the hippocampus of ControlΔSyn and IGF-
1RΔSyn mice. Magnification: 200x. 
 
3.16 Central IGF-1 receptor deficiency results in loss of 
spatial memory formation and anxiety-like behavior 
A plethora of neurodegenerative diseases, such as Alzheimer’s disease, have been 
associated with altered circulating insulin and IGF-1 concentrations (163). Moreover, 
IGF-1 levels decline with age, a well-known risk factor in the formation of 
neurodegenerative conditions (212). Many of these clinical syndromes are associated 
with disorders of learning and memory, processes that have been linked to the 
hippocampus. To analyze whether loss of central IGF-1 receptor signaling has any 
effect on learning and/or memory formation, IGF-1RΔSyn mice were submitted to a 
series of behavioral analysis. 
The Morris water maze is used to measure hippocampus-dependent learning, 
such as spatial memory. Spatial memories are formed after gathering and processing 
information about surroundings by vision and proprioception. Mice are placed in a 
basin filled with water and are trained in consecutive sessions to find a submerged 
platform. In a final session, the platform is removed and the time spent in each quadrant 
of the basin is recorded. ControlΔSyn mice showed a marked preference for the quadrant 
in which the platform was placed during training, indicating that they memorized the 
location of the platform, whereas IGF-1RΔSyn mice were unable to form long-term 
spatial memories (Fig. 55). 
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Fig. 55: Spatial navigation working memory is impaired in IGF-1RΔSyn mice.  
Water maze test performed on 6-month-old ControlΔSyn (black bars, n = 5) and IGF-1RΔSyn mice (white 
bars, n = 5) after acquisition training on day 7. Time spent in the quadrant previously containing the 
platform is depicted in %. Free exploration time lasted 60 s. Values are mean ± SEM. *P ≤ 0.05  versus 
time spent in other quadrants. 
 
The elevated plus-maze task is used to measure anxiety-like behavior. It is based 
on the observation that rodents prefer the closed arms of a maze to those without walls 
(193). The open arms of the maze combine the fear of a brightly-lit open field and the 
fear of balancing on a raised, constricted platform. The closed arms, by contrast, have 
high walls forming a narrow alley providing possible protection from potential 
predators. IGF-1RΔSyn mice exhibited great endurance to anxiety by staying in the open 
arms of the maze for a longer period than littermate controls (Fig. 56), indicating that 
lack of central IGF-1 receptor has a tranquilizing, anxiolytic effect. 
 
 
Fig. 56: IGF-1RΔSyn mice do not display signs of anxiety.  
Elevated plus-maze test performed on 6-month-old ControlΔSyn (black bars, n = 5) and IGF-1RΔSyn mice 
(white bars, n = 5). Time spent in the open arms is depicted in %.Values are mean ± SEM. *P ≤ 0.05  
versus controls. 
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Motor coordination was assessed using a rotarod apparatus. In this experiment, 
mice were placed on a horizontal motor-driven rotating rod, with the head directed 
against the direction of rotation, so that the mouse has to progress forward to avoid 
falling for a period of 5 minutes. IGF-1RΔSyn mice performed as well as control 
littermates in this task and managed to stay on the rotarod for the entire duration of the 
experiment (Fig. 57). 
 
 
Fig. 57: Unaltered motor coordination in IGF-1RΔSyn mice.  
Rotarod test performed on 6-month-old ControlΔSyn (black bars, n = 5) and IGF-1RΔSyn mice (white bars, n 
= 5). Values are mean ± SEM. 
 
The object recognition task is based on the spontaneous novelty-preference 
paradigm. Under normal circumstances mice will spend more time exploring a new 
object than a familiar one (213). No differences could be detected in the acquisition of 
visual recognition memory of IGF-1RΔSyn mice in comparison to littermate controls 
(Fig. 58), since both mouse strains exhibited similar preference towards the novel 
object, indicating that motivation and curiosity are unaltered. These findings were 
further confirmed using a photocell activity cage to determine exploratory behavior 
(Fig. 58). 
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Fig. 58: Unaltered spontaneous novelty preference and exploratory activity in IGF-1RΔSyn mice.  
(A) Preference assessed by object recognition task performed on 6-month-old ControlΔSyn (black bars, n = 
5) and IGF-1RΔSyn mice (white bars, n = 5). Values are mean ± SEM. (B) Number of movement 
detections during a 60-minute activity trial performed on 6-month-old ControlΔSyn (black bars, n = 5) and 
IGF-1RΔSyn mice (white bars, n = 5). Values are mean ± SEM.  
 
 In conclusion, these behavioral analyses indicate that IGF-1RΔSyn mice display 
an impaired spatial memory acquisition and a loss of reaction to anxiety-inducing 
stimuli. Motor coordination, object recognition and exploratory behavior, on the other 
hand, appear to function normally. 
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4 Discussion 
Resistance to the biological effects of the peptide hormone insulin represents one 
of the hallmarks during the development of type 2 diabetes (214, 215). Apart from the 
direct effect of impaired insulin action on the dysregulation of glucose and lipid 
homeostasis (23), insulin resistance predisposes to obesity, atherosclerosis and 
cardiovascular diseases (reviewed in (216-218)). Nevertheless, the exact molecular 
mechanisms leading to insulin resistance in patients suffering from type 2 diabetes are 
largely unknown and it remains unclear whether they are restricted to selective tissues 
or represent a more body wide phenomenon. 
 
4.1 Inducible mouse models of insulin resistance 
To elucidate the contribution of brain insulin signaling compared to peripheral 
insulin signaling with respect to the pathophysiology of insulin resistance, two novel, 
acutely inducible insulin receptor-deficient mouse models were employed: the IRΔwb 
mice show a strong reduction of the insulin receptor in all tissues including the CNS, 
whereas the IRΔper mice lack the insulin receptor only in the periphery. 
The IRΔper mouse model uses a Cre recombinase-steroid receptor fusion protein 
to acutely induce a peripheral insulin receptor knockout. These RosaCreERT2-
expressing mice show little or no recombination in brain, thought to be an effect of a 
lower local concentration of tamoxifen in the CNS (100). This is potentially attributable 
to low efficiency transport of tamoxifen through the blood-brain-barrier. Therefore, this 
model serves as a valuable tool for analyzing the effects of acutely induced peripheral 
insulin resistance.  
The IRΔwb mouse model employs the method of conditional RNAi-mediated 
gene knockdown through the expression of an ubiquitous insulin receptor-specific 
shRNA. In both models the onset of systemic insulin resistance can be modulated 
through administration of inducers, tamoxifen in the former and doxycycline in the 
latter. The successful generation of these two inducible insulin resistance models was 
demonstrated. They serve as an ideal model to study the role of insulin action and 
insulin resistance for the first time in the adult mouse devoid of any developmental 
compensation, thus bypassing any changes arising from deletion of the insulin receptor 
during embryonic development. As type 2 diabetes manifests itself during the later 
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stages of life in humans, the adult mouse model is likely to more accurately resemble 
human disease. 
 
4.2 Peripheral versus central insulin signaling 
Recent studies have provided increasing evidence for a role of neuronal insulin 
action in the maintenance of glucose homeostasis (219-223). Nevertheless, the debate 
continues whether insulin’s direct or indirect effects on peripheral tissues are more 
important determinants in these mechanisms. On the one hand, Edgerton et al. have 
shown that insulin’s direct effects on the liver regarding the control of hepatic glucose 
production prove dominant over indirect effects in conscious dogs (224). The 
importance of insulin’s direct effects has also been elaborately described by the analysis 
of liver insulin receptor knockout mice (LIRKO), which exhibit increased plasma 
insulin levels and signs of hepatic insulin resistance (135, 145). In contrast, the neuron-
specific insulin receptor knockout (NIRKO) mice show an increase in food intake and 
moderate signs of diet-dependent obesity but also impaired suppression of hepatic 
glucose production (134); evidence for a significant indirect effect of insulin signaling 
in the regulation of hepatic glucose production. This is supported by studies employing 
injections of antisense oligonucleotides (ASO) to impair insulin receptor signaling 
selectively in the mediobasal hypothalamus (219, 221). These controversial findings 
have been subject to extensive discussion and have been attributed to differences of 
glucose metabolism in different species (225). The present study reveals several novel 
aspects in understanding the consequences and particularly the relative contribution of 
CNS insulin action to metabolic regulation in adult mice. 
 
4.2.1 The role of central insulin action in lipogenesis 
Both IRΔper and IRΔwb mice display a significant reduction of white adipose 
tissue mass, which was to some extent expected due to the loss of inhibition of lipolysis 
by insulin as a result of the lack of adipocyte-autonomous insulin signal transduction. 
Surprisingly, the loss of epigonadal fat pads in IRΔwb mice is much more pronounced 
compared to IRΔper mice in the presence of the same degree of insulin receptor ablation 
in adipose tissue. Body composition analysis revealed a significantly more pronounced 
loss of fat mass in IRΔwb mice, while the size of other organs remained unaltered. 
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Recent studies suggest the presence of a new neuroendocrine circuit in the CNS 
involving ghrelin, which is responsible for the regulation of metabolism in adipose 
tissue (226). Chronic intracerebroventricular administration of ghrelin resulted in an 
increase in glucose and triglyceride uptake in white adipocytes, inhibition of lipid 
oxidation and a rise in lipogenesis (226). Our findings suggest a novel role for central 
insulin in this CNS neuroendocrine network of adipose metabolism. Chronic 
intracerebroventricular infusion of insulin into the lateral ventricle of C57BL/6 mice 
resulted in a slightly increased epigonadal fat pad, larger adipocytes and an increase in 
the fat-storage promoting enzyme lipoprotein lipase compared to mice receiving carrier 
infusion. As previously mentioned, isolated neuronal insulin resistance, either via 
tissue-specific knockout mouse models (134) or through injection of ASOs directed 
against the insulin receptor (219, 221), has been shown to result in mild obesity. The 
increase in body weight as a consequence of central insulin resistance appears to result 
from hyperphagia. Lateral intracerebroventricular infusion of insulin as used in the 
present study, on the other hand, has been shown not to alter food intake in rodents 
(227), but apparently allows access of insulin to brain areas regulating lipogenesis in 
white adipose tissue (Fig. 59), indicating a novel role for central insulin in the neuronal 
control of lipogenesis in addition to the well-documented cell-autonomous inhibition of 
lipolysis. Taken together, these results reveal differential, partially counterbalancing 
actions of insulin in the CNS; a catabolic function via control of food intake and an 
anabolic function via indirect stimulation of lipogenesis. These data are in line with the 
notion that insulin acts as a primary hormone to control metabolism, while its overall 
energy homeostasis-regulating function appears to be minor compared to leptin. 
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Fig. 59: Proposed model for insulin action in the CNS and in the periphery in the regulation of 
glucose and adipose tissue metabolism.  
Insulin is secreted from the pancreas and binds directly to insulin receptors on peripheral organs such as 
liver and adipose tissue, thereby mediating signals leading to the downregulation of gluconeogenesis and 
lipolysis. By binding and activating insulin receptors in the central nervous system, insulin action 
ultimately leads to the activation of hepatic IL-6 and the upregulation of lipogenic genes in white adipose 
tissue. 
 
4.2.2 Insulin-mediated inhibition of adipocyte-autonomous leptin 
secretion 
Since adipokine secretion is tightly correlated with the amount of adipose tissue 
(for review see (228)), the differential regulation of white adipose tissue mass observed 
in IRΔper and IRΔwb mice implied consequences for circulating leptin and adiponectin 
levels. Leptin acts as an essential endocrine signal to the hypothalamus in the control of 
food intake and energy balance (229). Until today, the effects of insulin on leptin 
expression remain controversial. In vitro, while several studies could detect only mild or 
no effects of insulin on leptin expression (230-232), others have described a stimulating 
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function for insulin on leptin expression and secretion in adipocytes (233-235). In vivo 
the contradiction persists, as some groups report that insulin does not regulate leptin 
expression or secretion (236, 237), yet others have found that insulin increases plasma 
leptin levels (238, 239). After induction of peripheral insulin resistance, IRΔper mice 
exhibit an increase in circulating leptin concentrations. In contrast, similar to previously 
published transgenic models of lipodystrophy (240), IRΔwb mice display very low 
circulating leptin levels. However, when correlated to the amount of epigonadal fat, 
leptin levels are tremendously increased to a similar extent in IRΔper mice and in IRΔwb 
mice. Thus, insulin appears to inhibit leptin secretion in a white adipose tissue-
autonomous manner, consistent with the idea that loss of insulin receptor signaling 
specifically in adipocytes results in a rise in leptin secretion from the adipose tissue. In 
IRΔwb mice, although adipocyte-autonomous leptin secretion is increased, absolute 
levels of circulating leptin are reduced as a consequence of the dramatic reduction in 
white adipose tissue mass. In IRΔper mice, however, the rise in serum leptin 
concentrations remains visible (Fig. 60).  
 
 
 
Fig. 60: Proposed model for the effects of insulin resistance on circulating leptin levels.  
As a result of the loss peripheral insulin receptor signaling, leptin secretion is disinhibited, resulting in an 
increase in circulating leptin levels detectable in IRΔper mice. In IRΔwb mice, however, this effect is 
masked by a dramatic reduction in white adipose tissue mass. 
 
Concomitantly, adiponectin concentrations of IRΔper mice and IRΔwb mice were 
found to be highly upregulated when correlated to white adipose tissue mass. This at 
first appears paradoxical, since it is well established that total plasma adiponectin is 
reduced in insulin resistant subjects. However, other studies have previously reported a 
contradictory hyperadiponectinemia in patients with severe insulin resistance due to 
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loss-of-function mutations in the insulin receptor (241). Strikingly, mutations in Akt2, a 
signaling molecule downstream of the insulin receptor in its signal transduction 
pathway, lead to low leptin and adiponectin concentrations, indicating that elevated 
adiponectin concentrations in the presence of impaired insulin receptor function may 
reflect a loss of inhibition of adiponectin expression by an Akt2-independent insulin 
signaling pathway in adipocytes (241). Further studies revealed that 
hyperadiponectinemia with loss of insulin receptor function was not dependent on 
developmental receptor dysfunction (242), a fact supported by the inducible IRΔper and 
IRΔwb mouse models of insulin resistance here employed. 
 
4.2.3 Hepatic Stat-3 activation and its role in peripheral glucose 
homeostasis 
Leptin mediates its effects by binding to the long isoform of the leptin receptor 
(ObRb) (243, 244). Both IRΔwb and IRΔper mice show an increase in mRNA expression 
of the hepatic long isoform of the leptin receptor, as well as a rise in shedding of hepatic 
ObRb as binding protein (245). Upregulation of ObRb expression in liver could 
therefore be either a direct consequence of impaired insulin action in hepatocytes or 
other peripheral tissues as it is observed to similar extents in both mouse models, or a 
secondary effect caused by increased leptin concentrations as has previously been 
published (246). However, a similar increase in ObR expression in hepatocyte-specific 
insulin receptor knockout mice indicates that insulin suppresses ObR expression in liver 
in a cell-autonomous fashion (247). 
Binding of leptin to the leptin receptor leads to receptor homodimerization 
followed by activation of the Janus Kinases (JAK) which in turn recruit and activate 
Signal transducer and activator of transcription (Stat) proteins. Activated Stat proteins 
dimerize and translocate to the nucleus, where they bind to the DNA and activate 
transcription of target genes (for review see (248)). In addition to elevated leptin levels 
and increased ObRb mRNA and protein expression, IRΔper mice exhibit significantly 
increased phosphorylation of hepatic Stat-3. In contrast, expression and tyrosine 
phosphorylation of Stat-3 in IRΔwb mice that display low plasma leptin concentrations in 
the presence of elevated ObRb mRNA and protein expression are unaltered.  
 Also, IL-6 mRNA expression in the liver is significantly increased in IRΔper mice 
after induction of insulin receptor deficiency, whereas it is unaltered in IRΔwb mice, 
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indicating a role for central insulin action in the regulation of hepatic IL-6 mRNA 
expression. Since Stat-3 is not only a target of leptin, but has recently been 
demonstrated to be a target of the brain insulin signaling pathway by regulation of 
hepatic IL-6 expression (199, 249), activation of hepatic Stat-3 may either result 
through intact neuronal insulin signal transduction leading to an upregulation of hepatic 
IL-6 mRNA expression or as a direct consequence of leptin signaling through the 
hepatic ObRb.  
 IRΔwb mice, lacking CNS insulin signaling, suffer from more severe 
hyperglycemia than IRΔper mice. Restoration of Stat-3 tyrosine phosphorylation in IRΔwb 
mice results in a significant improvement of hyperglycemia to normal blood glucose 
levels. Although these experiments cannot ultimately rule out whether improved 
glucose metabolism in IRΔper mice versus IRΔwb mice is a consequence of Stat-3 
phosphorylation caused by maintained IL-6 regulation controlled by insulin signaling in 
the brain or by elevated leptin concentrations in the presence of increased hepatic ObRb 
expression, these differential phenotypes of IRΔper and IRΔwb mice provide additional 
evidence for a physiologically relevant role of activated hepatic Stat-3 signaling in 
glucose homeostasis in mice. 
 
4.2.4 Effects of peripheral and central insulin deficiency on insulin 
concentrations and its secretion from the pancreatic β cell 
Pancreatic β cell insulin receptor knockout mice (βIRKO) suffer a loss of glucose-
stimulated insulin secretion (131). Strikingly, the IRΔper mice exhibited no detectable 
impairment in this pathway despite showing an insulin receptor deletion of more than 
95% in pancreas. A diminished first-phase insulin secretion is an early marker of β cell 
deterioration, yet this appears not to be the case in IRΔper mice. Fasting plasma insulin 
levels in IRΔwb mice were significantly higher than those found in IRΔper mice, 
consistent with a more severe degree of insulin resistance in this mouse model due to 
higher blood glucose concentrations. Accordingly, although a slight increase in insulin 
levels upon administration of an exogenous glucose challenge could be detected, the 
characteristic biphasic pattern of insulin secretion was not detectable. Though 
significantly enlarged, no structural defects could be detected in pancreatic islets of 
IRΔper and IRΔwb mice, nor was the distribution of β cells altered in either mouse model. 
This is a clear indication that the insulin receptor is not required for acute β cell 
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hyperproliferation, since β cell hyperplasia still occurs and the response to exogenously 
administered glucose remains unaltered. 
 
 
4.3 IGF-1 receptor signaling in the central nervous system 
4.3.1 Contribution of central IGF-1 receptor signaling to insulin-
mediated effects in the periphery 
Over the past few years it has become widely acknowledged that insulin has 
profound effects in the CNS, where it modulates a variety of functions including the 
regulation of energy homeostasis, sympathetic activity and peripheral glucose 
homeostasis (134, 221, 250, 251). However, the contribution of central IGF-1 receptor 
signaling to these processes has so far not been evaluated and may provide novel 
insights with respect to the pathogenesis of type 2 diabetes and the development of 
neurodegenerative disorders. To this end, IGF-1RΔSyn mice lacking the IGF-1 receptor 
specifically in Synapsin-1-expressing neurons were generated and efficient reduction in 
IGF-1 receptor protein expression was demonstrated in the hippocampus and in the 
parietal cortex of this mouse model.  
Analysis of energy and glucose homeostasis in IGF-1RΔSyn mice and control 
littermates indicate that the loss of IGF-1 receptor signal transduction in the 
hippocampus and cortex has no apparent influence on the regulation of blood glucose or 
leptin and insulin concentrations. Furthermore, administration of an exogenous glucose 
or insulin challenge is counter-regulated in a manner comparable to littermate controls.  
However, IGF-1RΔSyn mice display a reduced body weight compared to controls 3 
weeks after birth, at the age of weaning. Whether this reduced body weight is a result of 
an intrauterine growth retardation or arises from a postnatal growth deficit, potentially 
due to a deficiency in locating or in memorizing the location of the mother’s teat, 
remains to be determined. The reduced body weight is compensated for as early as one 
week after weaning and no further differences in body weight between IGF-1RΔSyn mice 
and littermate controls were detected. Concomitantly, epigonadal fat pads and body 
composition of adult mice lacking central IGF-1 receptor signaling are indistinguishable 
from those of controls. 
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In conclusion, IGF-1 receptor signaling in Synapsin-1-expressing neurons 
apparently has no impact on peripheral glucose or energy homeostasis in the presence 
of normal insulin signaling. However, one of the key regions involved in the regulation 
of food intake and energy expenditure is the hypothalamus. Thus, it remains to be 
determined whether deletion of the IGF-1 receptor in this particular region has any 
influence on peripheral metabolic actions. 
 
4.3.2 Neuroprotective effects of IGF-1 receptor signaling 
Several in vitro and in vivo studies have revealed IGF-1 to be a neuroprotective 
factor of hippocampal neurons with respect to the formation of neurodegenerative 
diseases such as Alzheimer’s and Huntington’s disease. IGF-1 significantly protected 
rat primary hippocampal neurons against neurotoxicity induced by Aβ derivatives 
(252). Moreover, in a rat model of Huntington’s disease, icv infusion of IGF-1 
significantly attenuated striatal degeneration after injection of the NMDA receptor 
agonist quinolinate (253).  
Injection of kainic acid (KA), a non-NMDA glutamate receptor agonist, induces 
excitatory neurotoxicity through acute membrane depolarization and latent cellular 
toxicity which results in neuronal apoptosis predominantly in the hippocampus. Loss of 
central IGF-1 receptor signaling, particularly in the hippocampus, would potentially 
result in a higher susceptibility of IGF-1RΔSyn mice to KA therefore leading to more 
severe seizures and increased apoptosis. Upon neuronal degeneration, the Nissl bodies 
of a neuron disintegrate and dispersion of the Nissl substance occurs, a process called 
chromatolysis. Staining of Nissl bodies therefore serves as an adequate indicator of 
neuronal damage. Interestingly, no differences could be detected in seizure initiation 
time and strength or in the brain morphology after KA injection between IGF-1RΔSyn 
mice and littermate controls, indicating that loss of IGF-1 receptor signaling in 
Synapsin-1-expressing neurons is potentially insufficient to abrogate IGF-1-mediated 
neuroprotection. This might also explain the indistinguishable weight of brain tissues of 
IGF-1RΔSyn mice and littermate controls, whereas IGF-1-deficient mice display a 
severely reduced brain size, particularly a diminished dentate gyrus granule cell layer 
(208). On the other hand, mice with an overactivation of Ras, a signaling molecule 
downstream of the IGF-1 receptor, exhibit severe brain hypertrophy (206). The 
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activation status of Ras and whether loss of Ras activation is compensated for by a 
signaling redundancy via the insulin receptor remains to be elucidated. 
 
4.3.3 IGF-1 receptor signaling in learning and memory formation 
Many neurodegenerative disorders, such as Alzheimer’s disease, are associated 
with disorders of learning and memory. Since declarative memory cannot be properly 
assessed in animal models, spatial memory formation in rodents is determined using the 
Morris water maze task (188). IGF-1RΔSyn mice performed poorly in this test, 
suggesting a significant impairment in the formation of long-term memories. The 
elevated plus maze task (193) was designed to assess stress behavior in combination 
with anxiety or depression. IGF-1RΔSyn mice did not display any signs of anxiety in the 
elevated plus maze, since, in contrast to control littermates, they did not exhibit 
preference for the closed arms of the maze, indicating that the loss of central IGF-1 
receptor signaling has an anxiolytic effect. Conversely, the performance of IGF-1RΔSyn 
mice did not differ from that of controls when analyzing the spontaneous novelty 
paradigm. However, previous studies have shown that hippocampal damage rarely 
produces significant deficits on object recognition tasks in rodents, suggesting that the 
hippocampus is not a central component necessary to discriminate familiarity of 
previously encountered objects (254).  
Western blot analyses reveal a significant reduction of IGF-1 receptor protein 
expression in the hippocampus and to a lesser degree in the parietal cortex of the brain. 
The parietal lobe has been implicated in the integration of sensory information 
determining spatial orientation and navigation, while the hippocampus is required for 
the formation of declarative memory. Loss of IGF-1 receptor signaling in these brain 
regions has a significant impact on the formation and recollection of spatial memories 
and results in reduced anxiety-like behavior. Thus, the present study clearly establishes 
a critical role for IGF-1 signaling in memory formation and/or retention. 
 
4.4 Perspectives and experimental approaches 
In conclusion, this thesis defines CNS insulin action as a pivotal determinant of 
energy homeostasis, peripheral glucose and fat metabolism in the adult mouse. The data 
support recent findings on the regulation of hepatic Stat-3 activation by central insulin 
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and indicate a novel role for CNS insulin action in the regulation of adipocyte 
metabolism. 
Furthermore, this thesis demonstrates that loss of IGF-1 receptor signaling in the 
hippocampus and in the parietal cortex results in a profound deficit in spatial memory 
acquisition and has an anxiolytic effect, while peripheral glucose and energy 
homeostasis remain unaffected.  
However, as previously mentioned, to entirely rule out any influence of IGF-1 
receptor signaling in the CNS on metabolic processes, further experiments are 
necessary, including deletion of the IGF-1 receptor in the hypothalamus by crossing 
mice homozygous for the loxP-flanked IGF-1 receptor allele with mice expressing the 
Cre recombinase under the control of a promoter expressed specifically in this brain 
region, such as for example the promoters for steroidogenic factor (Sf-) 1 or single-
minded (Sim) 1. 
In addition, to elucidate the underlying molecular mechanism behind the 
impaired spatial memory formation, current experiments include the measurement of 
long-term potentiation (LTP) in IGF-1RΔSyn mice and littermate controls, as well as the 
generation of a combined insulin receptor and IGF-1 receptor knockout in the CNS. 
These experiments will aid in determining a contribution of altered insulin and IGF-1 
receptor signaling in the central nervous system to the development of 
neurodegenerative diseases, obesity and diabetes mellitus type 2. 
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5 Summary 
Much of our understanding about insulin has been gained from murine knockouts 
of the insulin receptor (IR) gene in the whole body or restricted to individual tissues. 
Here, two novel inducible mouse models with IR inactivation in all tissues including 
brain (IR∆wb) or restricted to peripheral tissues (IR∆per) are described. Crucially, mouse 
models with inducible deletion later in life allow for the distinction between 
developmental and acute effects of insulin resistance.  
Compared to IR∆per mice, body wide deletion of IR has a more pronounced effect 
on reducing white adipose tissue mass (WAT), despite a similar reduction in IR 
expression in WAT of both models. The more pronounced lipodystrophy in IRΔwb mice 
points to a novel regulatory function of central insulin receptor signaling in control of 
lipogenesis which is substantiated by the ability of intracerebroventricularly applied 
insulin in C57BL/6 mice to slightly increase adipocyte size, fat mass and white adipose 
tissue lipoprotein lipase expression. Moreover, loss of insulin receptor signaling in 
adipocytes results in an increase in leptin secretion from the adipose tissue, indicating 
that insulin inhibits adipocyte-autonomous leptin secretion. In addition to the increase in 
leptin secretion, both strains display a dramatic upregulation of hepatic leptin receptor 
expression, while only IR∆per mice exhibit increased Stat-3 phosphorylation and IL-6 
expression. IRΔwb mice, on the other hand, display a higher degree of impaired 
peripheral glucose metabolism, which is ameliorated by leptin administration along 
with Stat-3 phosphorylation. Furthermore, despite exhibiting largely reduced IR 
expression in pancreas, IR∆per mice still secrete insulin in response to an acute glucose 
challenge, whereas glucose-stimulated insulin secretion is abrogated in IRΔwb mice, but 
both mouse models respond to hyperglycemia with a significant increase in β cell mass. 
In conclusion, these findings define CNS insulin action as a pivotal determinant of 
energy homeostasis and peripheral glucose metabolism in the adult mouse and support 
recent findings on the regulation of hepatic IL-6 mRNA by central insulin. 
Nevertheless, leptin-activated Stat-3 phosphorylation in liver may alternatively lead to 
improved glucose metabolism in IRΔwb mice.  
Furthermore, deletion of the insulin-like growth factor (IGF-) 1 receptor in the 
central nervous system reveals a significant role for IGF-1 receptor signaling in 
hippocampal learning and spatial memory acquisition and defines IGF-1R as a potential 
new therapeutic target in the treatment of conditions linked to anxiety-like behavior. 
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6 Zusammenfassung 
Der heutige Wissensstand über Insulin wurde zum größten Teil aus der Analyse 
von „Knockout“-Mäusen des Insulinrezeptor (IR) Gens im gesamten Körper oder in 
spezifischen Geweben gewonnen. Hier werden zwei neue, induzierbare Mausmodelle 
beschrieben, in denen der IR entweder in allen Geweben inklusive Gehirn (IR∆wb) oder 
nur in peripheren Geweben (IR∆per) inaktiviert werden kann. Die Möglichkeit einer 
Gendeletion, die erst im adulten Tier induziert wird, ist essentiell für die 
Differenzierung zwischen akuten und entwicklungsabhängigen Effekten der 
Insulinresistenz. Trotz gleichartiger IR-Inaktivierung im weißen Fettgewebe beider 
Mausmodelle, bewirkt die körperweite Deletion des IR eine stärkere Reduktion der 
weißen Fettmasse im Vergleich zu IR∆per Mäusen. Diese erhöhte Lipodystrophie in 
IR∆wb Mäusen deutet auf eine neue regulatorische Funktion des zentralen IR-
Signalweges in der Kontrolle der Lipogenese; eine Hypothese, die durch die Erkenntnis 
unterstützt wird, dass intracerebroventrikular infundiertes Insulin in C57BL/6 Mäusen 
zu einer Erhöhung von Adipozytengröße, Fettmasse und Lipoprotein Lipase mRNA 
Expression führt. Darüberhinaus resultiert der Verlust der IR-Signaltransduktion in 
Adipozyten in einer erhöhten Leptinsekretion. Beide Mausmodelle weisen ebenfalls 
eine erhöhte hepatische Leptinrezeptor Expression auf, wobei dies nur in IR∆per Mäusen 
auch zu einer verstärkten Stat-3-Phosphorylierung und einer gesteigerten IL-6 mRNA 
Expression führt. Im Gegensatz dazu weisen IR∆wb Mäuse eine stärkere 
Beeinträchtigung des peripheren Glukosemetabolismus auf, der, ebenso wie die Stat-3-
Phosphorylierung, durch chronische Leptininfusion normalisiert wird. Beide 
Mausmodelle reagieren auf Hyperglykämie mit einer signifikanten Zunahme der β-
Zellmasse, wobei die Glukose-stimulierte Insulinsekretion nur noch in IR∆per Mäusen 
funktioniert. Zusammenfassend belegen diese Ergebnisse eindeutig, dass die zentrale 
Insulinsignaltransduktion wesentlich für die Regulation des peripheren 
Energiehaushaltes und Glukosemetabolismus der Maus ist. Zudem unterstützen sie 
bereits vorhandene Erkenntnisse zur Regulation hepatischer IL-6 mRNA durch 
zentrales Insulin. Allerdings besteht die Möglichkeit, dass die Leptin-aktivierte Stat-3-
Phosphorylierung in der Leber von IR∆wb Mäusen zur Verminderung der 
Hyperglykämie führt.  
Des Weiteren weist die Deletion des IGF-1 Rezeptorgens im zentralen 
Nervensystem auf eine relevante Rolle der IGF-1 Signaltransduktion bei der Bildung 
Zusammenfassung    
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räumlicher Erinnerungen hin und liefert einen neuen potenziellen Ansatz für die 
Behandlung von Angstzuständen. 
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